TABLE OF CONTENTS
Volume 77, Issue 2 (February 2005)
American Society for Clinical Pharmacology and Therapeutics
Data mining clinical records to detect adverse events
T. S. Coster MD, A. Szarfman MD, PhD, D. Fram MS and C. Russell MS, WRAIR, FDA
Clin Pharmacol Ther 77: P1-P1; doi:10.1016/j.clpt.2004.11.007
Clinical and economic consequences of formulary restrictions for three leading proton pump inhibitors
S. Schneeweiss MD, ScD, M. Maclure ScD, C. Dormuth MA, MS, R. J. Glynn PhD, ScD, C. Canning MS and J. Avorn MD
Clin Pharmacol Ther 77: P1-P1; doi:10.1016/j.clpt.2004.11.008
PK/PD modeling of the interaction between IV scopolamine (SCP) and physostigmine (PHY) in healthy elderly volunteers
Y. Men MD, PhD, K. Wesnes PhD and J. Venitz MD, PhD, FDA
Clin Pharmacol Ther 77: P2-P2; doi:10.1016/j.clpt.2004.11.009
Effect of NONMEM minimization status and number of replicates on bootstrap parameter distributions for population pharmacokinetic models: A case study
M. R. Gastonguay PhD and A. El-Tahtawy PhD
Clin Pharmacol Ther 77: P2-P2; doi:10.1016/j.clpt.2004.11.010
Does sex influence proximal small intestinal CYP3A or P-GP expression?
M. F. Paine RPh, PhD, S. S. Ludington BS, M. L. Chen PhD, P. W. Stewart PhD, S. M. Huang PhD and P. B. Watkins MD
Clin Pharmacol Ther 77: P2-P2; doi:10.1016/j.clpt.2004.11.011
Uremic toxins inhibit hepatic uptake of eprosartan
H. Sun MD, PhD, Y. Huang MD, PhD, H. Okochi PhD, L. Frassetto MD and L. Z. Benet PhD
Clin Pharmacol Ther 77: P2-P2; doi:10.1016/j.clpt.2004.11.012
Dose effects of respiratory neoantigen exposure on primary allergic sensitization
M. A. Riedl MD, E. M. Landaw MD, PhD, A. Saxon MD and D. Diaz-Sanchez PhD
Clin Pharmacol Ther 77: P3-P3; doi:10.1016/j.clpt.2004.11.013
Effect of CYP3A5 genotype on the extent of CYP3A inhibition by verapamil
Y. Wang PhD, Y. Jin MD, J. K. Hilligoss JPN, H. Ho MD, M. A. Hamman BS, Z. Hu MD, PhD, J. C. Gorski PhD and S. D. Hall PhD
Clin Pharmacol Ther 77: P3-P3; doi:10.1016/j.clpt.2004.11.014
Guided cardiogenesis for safe stem cell-based therapy
A. Behfar, C. Perez-Terzic, D. M. Hodgson, A. E. Alekseev, G. C. Kane, M. Puceat and A. Terzic
Clin Pharmacol Ther 77: P3-P3; doi:10.1016/j.clpt.2004.11.015
Guanylyl cyclase C prevents colon carcinoma cell metastasis
W. J. Lubbe BSc, Z. Y. Zhou MD, W. Fu MD, S. Schulz PhD, R. J. Muschel MD, PhD, S. A. Waldman MD, PhD and G. M. Pitari MD, PhD
Clin Pharmacol Ther 77: P3-P3; doi:10.1016/j.clpt.2004.11.016
Menopausal status and estrogen receptor genotypes influenced the severity of hot flashes after tamoxifen treatment
Y. Jin MD, T. Skaar PhD, A. Storniolo MD, Z. Desta PhD, A. Nguyen, L. Li PhD, D. Hayes MD, D. A. Flockhart MD, PhD and V. Stearns MD
Clin Pharmacol Ther 77: P4-P4; doi:10.1016/j.clpt.2004.11.017
Genome-wide approach to finding determinants of susceptibility to chemotherapeutic agents
S. Shukla MPH, J. Badner MD, PhD, C. Cheng PhD, W. Bleibel BA and M. E. Dolan PhD
Clin Pharmacol Ther 77: P4-P4; doi:10.1016/j.clpt.2004.11.018
Grapefruit juice ingestion reduces talinolol serum concentration
U. I. Schwarz MD, D. Seemann, R. Oertel PhD, S. Miehlke MD, E. Kuhlisch PhD, M. F. Fromm MD, R. B. Kim MD, D. G. Bailey PhD and W. Kirch MD
Clin Pharmacol Ther 77: P4-P4; doi:10.1016/j.clpt.2004.11.019
CYP2A6 genotype and toxicity of nicotine in never smokers
D. A. Dempsey MD, P. Jacob III PhD, R. F. Tyndale PhD, E. Hoffmann MSc and N. L. Benowitz MD
Clin Pharmacol Ther 77: P4-P4; doi:10.1016/j.clpt.2004.11.020
Effect of CYP3A5 genotype on ketoconazole induced QT prolongation
R. Vuppalanchi MD, A. Lucksiri PharmD, L. Lang PhD, J. Hilligoss LPN, D. Flockhart MD, PhD and S. Hall PhD
Clin Pharmacol Ther 77: P5-P5; doi:10.1016/j.clpt.2004.11.021
Synephrine pharmacokinetics and cardiovascular changes after ingestion of citrus aurantium dietary supplements
C. A. Haller MD, M. Duan, P. Jacob III PhD and N. L. Benowitz MD
Clin Pharmacol Ther 77: P5-P5; doi:10.1016/j.clpt.2004.11.022
Human response to alpha-2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: Biphasic influence of dose, age, gender, and receptor genotype
D. King MD
Clin Pharmacol Ther 77: P5-P5; doi:10.1016/j.clpt.2004.11.023
Human sympathetic activation by alpha-2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism
P. LeCorre PhD
Clin Pharmacol Ther 77: P6-P6; doi:10.1016/j.clpt.2004.11.024
Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: Prediction of catecholamines and response to stress in twins
L. Zhang MD
Clin Pharmacol Ther 77: P6-P6; doi:10.1016/j.clpt.2004.11.025
The catecholamine release inhibitory peptide catestatin (chromogranin A[CHGA]352–372): A naturally occurring amino acid variant (GLY364SER) causes profound alterations in human autonomic activity
F. Rao MD
Clin Pharmacol Ther 77: P6-P6; doi:10.1016/j.clpt.2004.11.026
Catestatin, the catecholamine release-inhibitory peptide fragment of chromogranin A: Naturally occurring human variants displaying different potencies for multiple nicotinic cholinergic responses in chromaffin cells
S. K. Mahata PhD, M. Mahata PhD, G. Wen PhD, W. B. Wong MS, N. R. Mahapatra PhD, B. A. Hamilton PhD and D. T. O'Connor MD
Clin Pharmacol Ther 77: P6-P6; doi:10.1016/j.clpt.2004.11.027
Genetic variation in the human 
2B-ADRENERGIC receptor gene: Haplotypes and yohimbine response
J. P. Etzel BS, B. K. Rana PhD, G. Wen PhD, R. J. Parmer MD, N. J. Schork PhD, D. T. O'Connor MD and P. A. Insel MD
Clin Pharmacol Ther 77: P7-P7; doi:10.1016/j.clpt.2004.11.028
Pharmacogenomics of atrial fibrillation
B. S. Donahue, D. Darbar, A. L. George Jr., C. Li, N. J. Brown, M. Ritchie and D. M. Roden
Clin Pharmacol Ther 77: P7-P7; doi:10.1016/j.clpt.2004.11.029
Genomic screening as a starting point for studies of ion channel structure-function
D. M. Roden MD
Clin Pharmacol Ther 77: P7-P7; doi:10.1016/j.clpt.2004.11.030
A top-down, step up approach to pharmacogenetic discovery using CEPH family cell lines
A. Kraja PhD, J. Watters PhD, R. Lazarus PhD, Q. Zhang PhD, M. Markus BS, H. McLeod PharmD and M. Province PhD
Clin Pharmacol Ther 77: P8-P8; doi:10.1016/j.clpt.2004.11.031
Association of corticotropin releasing factor receptor-2 variants with response to inhaled glucocorticoids in asthma
E. S. Silverman MD, S. L. Lake PhD, K. G. Tantisira MD, B. G. Richter BS, A. A. Litonjua MD, R. Lazarus MD, J. Valone BS, S. A. Shore PhD and S. T. Weiss MD
Clin Pharmacol Ther 77: P8-P8; doi:10.1016/j.clpt.2004.11.032
Effect of pre-operative oral sustained-release morphine sulfate on post-operative morphine requirements in elective spine surgery
E. Bellissant MD, PhD, J. P. Estebe MD, PhD, V. Sebille PhD and C. Ecoffey MD
Clin Pharmacol Ther 77: P8-P8; doi:10.1016/j.clpt.2004.11.033
Gene expression in the arachidonic acid pathway due to tissue injury and inflammation, an NSAID, and COXIB in a clinical model of pain
X. M. Wang MD, PhD, T. X. Wu PhD, Y. S. Lee DDS, MS and R. A. Dionne DDS, PhD, PNMB
Clin Pharmacol Ther 77: P8-P8; doi:10.1016/j.clpt.2004.11.034
Effects of a dual COX-1/-2 inhibitor and a selective COX-2 inhibitor on pro-inflammatory gene expression in a clinical model of tissue injury
Y. Lee DDS, MS, H. Kim DDS, PhD, C. Rodriguez DDS, MS and R. A. Dionne DDS, PhD
Clin Pharmacol Ther 77: P9-P9; doi:10.1016/j.clpt.2004.11.035
Assessment of naltrexone antagonism of buprenorphine
M. Escher MD, J. Chabert, Y. Daali, V. Piguet, P. Dayer and J. Desmeules
Clin Pharmacol Ther 77: P9-P9; doi:10.1016/j.clpt.2004.11.036
Thermoregulation during endotoxemia in mice lacking inducible nitric oxide synthase: Involvment of the arginine-vasopressin
R. S. Saia MSc and E. C. Carnio PhD
Clin Pharmacol Ther 77: P9-P9; doi:10.1016/j.clpt.2004.11.037
Vasopressin release during endotoxemic shock in mice lacking inducible nitric oxide synthase
E.C. Carnio PhD
Clin Pharmacol Ther 77: P9-P9; doi:10.1016/j.clpt.2004.11.038
Lack of dextromethorphan interaction with P-glycoprotein
M. Kanaan PharmD, Y. Daali PhD, PharmD, P. Dayer Prof and J. Desmeules MD
Clin Pharmacol Ther 77: P10-P10; doi:10.1016/j.clpt.2004.11.039
Darifenacin, an M3 selective receptor antagonist (M3 SRA), does not prolong QT/QTC
A. Skerjanec PhD, M. B. Affrime, S. Milosavljev, D. B. Serra and Y. Wang
Clin Pharmacol Ther 77: P10-P10; doi:10.1016/j.clpt.2004.11.040
Effect of dronedarone on renal function in healthy subjects
Y. Tschuppert MD, T. Buclin MD, L. E. Rothuizen MD, L. A. Decosterd PhD, M. Appenzeller, C. Gaud MD and J. Biollaz MD
Clin Pharmacol Ther 77: P10-P10; doi:10.1016/j.clpt.2004.11.041
Phosphodiesterase-5 inhibition enhances sympathetically mediated vascular tone
J. M. Dopp PharmD, A. Win MD, C. A. Sinkey RN, W. G. Haynes MD and B. G. Phillips PharmD
Clin Pharmacol Ther 77: P10-P10; doi:10.1016/j.clpt.2004.11.042
Plasminogen activator inhibitor-1 (PAI-1) expression in vascular smooth muscle cells involves a SRC/MEK/USF signal cascade
P. J. Higgins PhD
Clin Pharmacol Ther 77: P11-P11; doi:10.1016/j.clpt.2004.11.043
Beyond hemostasis: The antiflammatory and antioxidant effects of dipyridamole
S. Chakrabarti PhD, O. Vitseva PhD, D. Iyu BS, S. Varghese MS and J. Freedman MD
Clin Pharmacol Ther 77: P11-P11; doi:10.1016/j.clpt.2004.11.044
Comparison of irbesartan versus atorvastatin therapy on angiotensin II (ANG II)-induced venoconstriction and plasma levels of angiotensin-(1–7)[ANG-(1–7)] in healthy volunteers
C. Schindler MD, K. B. Brosnihan PhD, C. M. Ferrario MD and W. Kirch MD
Clin Pharmacol Ther 77: P11-P11; doi:10.1016/j.clpt.2004.11.045
The selective alpha2-adrenergic receptor agonist dexmedetomidine (DEX) does not affect aortic pressure augmentation
D. Kurnik MD, G. G. Sofowora MD, M. Muszkat MD, P.A. Harris PhD, A. J. Wood MD and C. M. Stein MD
Clin Pharmacol Ther 77: P11-P11; doi:10.1016/j.clpt.2004.11.046
The effect of bosentan on endothelial function in patients with congestive heart failure
V. Dishy MD, N. Uriel MD, C. Stein MD, A. Golik MD, Z. Vered MD and G. Cotter MD
Clin Pharmacol Ther 77: P12-P12; doi:10.1016/j.clpt.2004.11.047
QT interval analyses from a placebo and positive controlled study evaluating the electrophysiological effects of duloxetine at supratherapeutic doses
L. Zhang, M. Derby, C. Gonzales, J. Chappell, R. Lucas, D. Small, M. P. Knadler and J. T. Callaghan
Clin Pharmacol Ther 77: P12-P12; doi:10.1016/j.clpt.2004.11.048
A definitive QT study incorporating step-wise dose escalation to steady-state
M. Derby, M. Gates, D. Small and J. T. Callaghan
Clin Pharmacol Ther 77: P12-P12; doi:10.1016/j.clpt.2004.11.049
Evaluation of drug interaction data in prescribing information for NMEs approved in 2000–2004
C. Collins MD, H. Hachad PharmD, I. Ragueneau MD and R. Levy PhD
Clin Pharmacol Ther 77: P12-P12; doi:10.1016/j.clpt.2004.11.050
Labeling of drugs that interact with oral contraceptives
M. Kim PharmD, E. Castillo BS, V. R. Jarugula PhD, A. Parekh PhD, L. A. Furlong MD, J. P. Hunt BS and H. J. Malinowski PhD
Clin Pharmacol Ther 77: P13-P13; doi:10.1016/j.clpt.2004.11.051
Effect of gastrointestinal function regulatory Kampo medicine, Dai-kenchu-to on human plasma calcitonine gene-related peptide, substance P and somatostatin levels
Y. Sato, F. Katagiri, S. Inoue, H. Itoh and M. Takeyama
Clin Pharmacol Ther 77: P13-P13; doi:10.1016/j.clpt.2004.11.052
Development of a QT database with analytic tools: Preliminary results
L. Kenna PhD, H. Sun PhD, C. Ahwah, M. Li MS, S. Lee PhD, J. Choi MS, N. Stockbridge MD, PhD, A. Parekh PhD and H. Malinowski PhD, FDA
Clin Pharmacol Ther 77: P13-P13; doi:10.1016/j.clpt.2004.11.053
Free-text information retrieval system for a rapid enrollment of patients into clinical trials
M. Averbuch MD, O. Maimon PhD, L. Rokach PhD and E. Ezer
Clin Pharmacol Ther 77: P13-P13; doi:10.1016/j.clpt.2004.11.054
Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema
B. Rosenkranz MD, K. Bork, J. Frank, W. Kreuz, L. Dong and J. Knolle
Clin Pharmacol Ther 77: P14-P14; doi:10.1016/j.clpt.2004.11.055
Effect of exenatide on lisinopril pharmacodynamics in patients treated for hypertension
P. Kothare PhD, H. Linnebjerg PhD, M. Atkins PhD, K. Mace PhD and M. Mitchell MD
Clin Pharmacol Ther 77: P14-P14; doi:10.1016/j.clpt.2004.11.056
Lack of pharmacokinetic interaction between muraglitazar, a novel dual PPAR /
agonist, and fenofibrate
R. Mosqueda-Garcia MD, PhD, D. Reitberg, C. Munsick, R. Darbenzio, S. Nepal, R. Reeves and A. Swaminathan
Clin Pharmacol Ther 77: P14-P14; doi:10.1016/j.clpt.2004.11.057
Effect of fluvoxamine, paroxetine and ketoconazole on the multiple dose pharmacokinetics of cilansetron in healthy male and female volunteers
M. deBruijn PhD, P. Boon PhD, T.L. ZumBrunnen PharmD and M. deVries PhD, PharmD
Clin Pharmacol Ther 77: P14-P14; doi:10.1016/j.clpt.2004.11.058
Duration of the gastric acid antisecretory effect of AZD0865 in dogs
B. Holstein PhD, A. Holmberg BSc, M. Florentzson BSc, A. Aurell Holmberg M Med Sci, M. Andersson MSc and K. Andersson PhD
Clin Pharmacol Ther 77: P15-P15; doi:10.1016/j.clpt.2004.11.059
Inhibition of PKC 
by ruboxistaurin 'RBX' does not enhance the blood pressure 'BP' response to glyceryl trinitrate 'GTN'
J. Voelker MD, C. Benson MD, PhD and M. Seger MS
Clin Pharmacol Ther 77: P15-P15; doi:10.1016/j.clpt.2004.11.060
Use of IV isoproterenol test as a biomarker in a first-in-man study: Pilot investigation with LY, a combined beta3 agonist/beta1 antagonist
J. Satterwhite PhD, S. di Virgilio PhD, J.J. VanLier MD, G. Gaich MD and S. Chalon MD, PhD
Clin Pharmacol Ther 77: P15-P15; doi:10.1016/j.clpt.2004.11.061
Bile acids (BA) induce heparin-binding EGF-LIKE growth factor (HB-EGF) expression in human gastroesophageal (GE) adenocarcinoma cells
L. Gong MD, PhD, P. Debruyne MD, PhD, S. Schulz PhD and S. Waldman MD, PhD
Clin Pharmacol Ther 77: P15-P15; doi:10.1016/j.clpt.2004.11.062
Effect of botanical supplementation on cytochrome P450 phenotypes in the elderly
B.J. Gurley PhD, S.F. Gardner PharmD, M.A. Hubbard MS, D.K. Williams PhD and W.B. Gentry MD
Clin Pharmacol Ther 77: P16-P16; doi:10.1016/j.clpt.2004.11.063
Change in erythropoietin pharmacokinetics in patients receiving hematopoietic stem cell transplantation
R.J. Hohl MD, PhD, J. Widness MD, S. Robert PhD, F. Goldman MD, N. Al-Huniti and P. Veng-Pederson PharmD
Clin Pharmacol Ther 77: P16-P16; doi:10.1016/j.clpt.2004.11.064
Frequency of eNOS polymorphisms in pediatric patients with sickle cell disease
K.A. Neville, T.C. Skaar, M.E. Heiny, G.L. Kearns and D.A. Flockhart
Clin Pharmacol Ther 77: P16-P16; doi:10.1016/j.clpt.2004.11.065
Targeted therapy for the treatment of imatinib-resistant chronic myeloid leukemia: A pharmacogenetic analysis
N. Shah MD, PhD, J. Nicoll and C. Sawyers
Clin Pharmacol Ther 77: P17-P17; doi:10.1016/j.clpt.2004.11.066
Pharmacokinetics (PK) and pharmacodynamics (PD) of palifermin (PAL) (a R-HUKGF molecule)
P. Zia-Amirhosseini PhD, M. Salfi, W. Yates, B. Gillespie, P. Leese, R. Rohwer and J. Sullivan
Clin Pharmacol Ther 77: P17-P17; doi:10.1016/j.clpt.2004.11.067
Clinical evaluation and comparison of erythropoietic growth factors for chemotherapy-induced anemia (CIA)
S. Bilic PharmD, A.B. Ogundele PharmD, C.M. Rubino PharmD and P.F. Smith PharmD
Clin Pharmacol Ther 77: P17-P17; doi:10.1016/j.clpt.2004.11.068
Lack of pharmacokinetic (PK) interactions between lonafarnib (L) and imatinib (I)
Y. Zhu MS, P. Statkevich PhD, D. Curtis MS and M. Sugrue MD, PhD
Clin Pharmacol Ther 77: P17-P17; doi:10.1016/j.clpt.2004.11.069
Individual pharmacokinetics play a major role in toxicity of the BEACOPP polychemotherapy regimen in Hodgin's disease
S. Wilde BSc, A. Jetter MD, S. Rietbrock MD, D. Kasel PhD, M. Sieber MD, H. Tesch MD, G. Hempel PhD, S. Reif PhD, U. Jaehde PhD, U. Merkel PhD, D. Busse MD, M. Schwab MD, V. Diehl MD and U. Fuhr MD
Clin Pharmacol Ther 77: P18-P18; doi:10.1016/j.clpt.2004.11.070
Quine pharmacokinetics and pharmacodynamics in children with falciparum malaria
M. Le Jouan PharmD, V. Jullien PharmD, E. Tetanye Ekoe MD, A. Tran PharmD, PhD, E. Rey PhD, J. Treluyer MD, PhD, M. Tod PhD and G. Pons MD, PhD
Clin Pharmacol Ther 77: P18-P18; doi:10.1016/j.clpt.2004.11.071
Concomitant intake of tenofovir disoproxil fumarate (TDF) does not impair plasma exposure of ritonavir (RTV) boosted atazanavir (ATV) in HIV-1 infected adults
N.V. Hentig MD, A. Haberl MD, T. Lutz MD, S. Klauke MD, M. Kurowski MD, S. Harder MD and S. Staszewski MD
Clin Pharmacol Ther 77: P18-P18; doi:10.1016/j.clpt.2004.11.072
Pronounced inhibition of both intestinal and hepatic cytochrome P450 3A4 activity by lopinavir/ritonavir in HIV infected patients
A. Jetter MD, C. Wyen MD, T. Klaassen MSc, F. Abdulrazik BSc, G. Fätkenheuer MD and U. Fuhr MD
Clin Pharmacol Ther 77: P19-P19; doi:10.1016/j.clpt.2004.11.073
Single and multiple dose pharmacokinetics (PK) of maribavir (MB) in healthy adults
J.D. Ma PharmD, A.N. Nafziger MD, MHS, S.A. Villano MD, J. Victory BSN and J.S. Bertino PharmD
Clin Pharmacol Ther 77: P19-P19; doi:10.1016/j.clpt.2004.11.074
Effect of the anti-cytomegalovirus (CMV) drug maribavir (MB) on the activities of cytochrome p450 (CYP) 1A2, 2C9, 2C19, 2D6, 3A, N-ACETYLTRANSFERASE-2 (NAT-2), and xanthine oxidase (XO) as assessed by the cooperstown 5+1 drug cocktail
J.D. Ma PharmD, A.N. Nafziger MD, MHS, S.A. Villano MD, A. Gaedigk PhD, J. Victory BSN and J.S. Bertino PharmD
Clin Pharmacol Ther 77: P19-P19; doi:10.1016/j.clpt.2004.11.075
Pharmacodynamic (PD) target attainment (TA) in normal size (N), OBESE (OB) and morbidly obese (Mob) healthy volunteers (HV) receiving one gram doses of ertapenem (ETP)
M. Chen PharmD, A.N. Nafziger MD, MHS and J.S. Bertino PharmD
Clin Pharmacol Ther 77: P20-P20; doi:10.1016/j.clpt.2004.11.076
Simulation-based support of dose recommendations of entecavir for renally impaired subjects
F. LaCreta PhD, D. Mould PhD, M. Bifano MS, D.M. Grasela PharmD PhD and M. Pfister MD FCP
Clin Pharmacol Ther 77: P20-P20; doi:10.1016/j.clpt.2004.11.077
Estimating seminal vesicle (SV) and prostate (PR) gland concentrations of drugs using linear regression of gland-specific biochemical markers in split ejaculate fractions
T.T. Ndovi MD, T.L. Parsons PhD and C.W. Hendrix MD
Clin Pharmacol Ther 77: P20-P20; doi:10.1016/j.clpt.2004.11.078
The association between cyclooxygenase gene polymorphisms and acute post-surgical pain in humans
P.D. Mittal-Parikh BS, H. Kim DDS, PhD, J. Brahim DDS, MS, J. Rowan RN, MS and R.A. Dionne DDS, PhD
Clin Pharmacol Ther 77: P20-P20; doi:10.1016/j.clpt.2004.11.079
Pharmacokinetic population modeling of nicotine incorporating CYP2A6 genotypes following different routes of administration
Y. Yoon MD, PhD, D. Verotta PhD and N. Benowitz MD
Clin Pharmacol Ther 77: P21-P21; doi:10.1016/j.clpt.2004.11.080
OATP-C(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients
K. Morimoto MS, S. Ueda MD, N. Seki MD, Y. Igawa MS, Y. Kameyama MS, A. Shimizu MS, T. Oishi BS, M. Hosokawa PhD, K. Iesato MD, S. Mori MD, Y. Saito MD and K. Chiba PhD
Clin Pharmacol Ther 77: P21-P21; doi:10.1016/j.clpt.2004.11.081
Pharmacogenetic variants influence tamoxifen's estrogenic effect on bone density
A.T. Nguyen BSc, Y. Jin MD, M. Rehman MD, L. Li PhD, T.C. Skaar PhD, V. Stearns MD, D.F. Hayes MD and D.A. Flockhart MD, PhD
Clin Pharmacol Ther 77: P21-P21; doi:10.1016/j.clpt.2004.11.082
Heritability of digoxin pharmacokinetics
D.L. Kroetz PhD, T. Nguyen BS, T. Giang PharmD, L. Hodges BS, R. Castro MD, E.T. Lin PhD, C. Brett MD and G. Swan PhD
Clin Pharmacol Ther 77: P21-P21; doi:10.1016/j.clpt.2004.11.083
Guanylyl cyclase C (GC-C) regulates the dynamics of the proliferating compartment of intestinal crypts
P. Li, R. Baksh, S. Schulz, S. Waldman and G. Pitari
Clin Pharmacol Ther 77: P22-P22; doi:10.1016/j.clpt.2004.11.084
Human aromatase (CYP19) pharmacogenomics: Gene resequencing and functional genomics
C. Ma MD, PhD, A. Adjei PhD, O. Salavaggione MD, L. Wang MD, PhD, B. Eckloff BA, E. Wieben PhD, A. Adjei MD, PhD and R. Weinshilboum MD
Clin Pharmacol Ther 77: P22-P22; doi:10.1016/j.clpt.2004.11.085
Beta 2-adrenergic receptor (B2AR) polymorphisms and antihypertensive response to beta-blocker therapy in the invest trial
Y. Gong PhD, A.L. Beitelshees PharmD, L. Stauffer, K. Gaston, A. Sloan, H.N. Yarandi PhD, T.Y. Langaee PhD, R.M. DeHoff PharmD, C.J. Pepine MD and J.A. Johnson PharmD
Clin Pharmacol Ther 77: P22-P22; doi:10.1016/j.clpt.2004.11.086
Effects of combined CYP2C9 and 2C19 polymorphism on the pharmacokinetics of glibenclamide in Chinese subjects
O.Q. Yin PhD, B. Tomlinson and M.S. Chow
Clin Pharmacol Ther 77: P23-P23; doi:10.1016/j.clpt.2004.11.087
CYP2C19 genotype predicts duration of response to tamoxifen in advanced breast cancer
R. van Schaik PhD, E. Teuling, M. Meijer, I. van der Heiden, M. van Fessem, M. van Vliet, I. van Staveren, M. Look, J. Klijn PhD, MD, J. Foekens PhD, J. Lindemans PhD and E. Berns PhD
Clin Pharmacol Ther 77: P23-P23; doi:10.1016/j.clpt.2004.11.088
Hepatocyte nuclear factors (HNF) 4 and 1 synergistically up-regulate car-mediated transcriptional activity of human CYP2C9 gene
H.G. Xie MD, PhD, W. Lee PhD, C. Yu PhD, C.M. Stein MD and R.B. Kim MD
Clin Pharmacol Ther 77: P23-P23; doi:10.1016/j.clpt.2004.11.089
Human sulfotransferase (SULT) 1A3 pharmacogenetics: Gene duplication and functional genomics
M. Hildebrandt BS, O. Salavaggione MD, Y. Martin BS, H. Flynn BS, S. Jalal PhD, E. Wieben PhD and R. Weinshilboum MD
Clin Pharmacol Ther 77: P23-P23; doi:10.1016/j.clpt.2004.11.090
Functional characterization of SNP and haplotype of human MDR1 gene using a vaccinia virus expression system
J. Oh PharmD, C. Kimchi-Sarfaty PhD, I. Kim PhD, A. Sherman, S. Ambudkar PhD and M. Gottesman MD
Clin Pharmacol Ther 77: P24-P24; doi:10.1016/j.clpt.2004.11.091
CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans
A. Llerena MD, PhD, P. Dorado PhD, M.C. Caéceres BSc, M.L. Wong MD and J. Licinio MD
Clin Pharmacol Ther 77: P24-P24; doi:10.1016/j.clpt.2004.11.092
Genetic variants of CYP2B6 decrease rate of efavirenz metabolism in vitro
Z. Desta PhD1, B.A. Ward BSc, D.A. Flockhart MD, PhD, T. Richter PhD, K. Klein PhD and U.M. Zanger PhD
Clin Pharmacol Ther 77: P24-P24; doi:10.1016/j.clpt.2004.11.093
Effect of age on the activity of cytochrome P450 2D6 using dextromethorphan phenotyping in humans
J. Park MD, K. Kim PhD, P. Park MD, PhD, D. Lee MD, H. Kim MD, C. Park MD, PhD and J. Shin
Clin Pharmacol Ther 77: P24-P24; doi:10.1016/j.clpt.2004.11.094
Sequence analysis of the 2B-ADRENERGIC receptor (ADRA2B) gene and in-vivo functional effects of novel variants
M. Muszkat MD, G.G. Sofowora MD, D. Kurnik MD, J. Solus PhD, L. Jiang MS, S.M. Williams PhD, E. Dawson PhD, A.J. Wood MD and C.M. Stein MD
Clin Pharmacol Ther 77: P25-P25; doi:10.1016/j.clpt.2004.11.095
Genetic determinants of UGT1A1 inducibility
J. Ramirez MS, F. Innocenti MD, PhD, B. J. Komoroski PharmD, S. Mirkov MS, A. Yoder Graber BA, D. Fackenthal BA, BS, S. Das PhD, E. G. Schuetz PhD, S. C. Strom PhD and M. J. Ratain MD
Clin Pharmacol Ther 77: P25-P25; doi:10.1016/j.clpt.2004.11.096
Adenylate cyclase type 9 (AC9) polymorphism and in vivo vascular response
H. G. Xie MD, PhD, V. Dishy MD, G. G. Sofowora MD, A. J. Wood MD, R.B. Kim MD and C. M. Stein MD
Clin Pharmacol Ther 77: P25-P25; doi:10.1016/j.clpt.2004.11.097
Effect of different alleles on CYP2D6 activity
S. Borges MD, D. R. Jones PhD, A. Bermes BSc, T. C. Skaar PhD and S. D. Hall PhD
Clin Pharmacol Ther 77: P25-P25; doi:10.1016/j.clpt.2004.11.098
Duration of human MU opiate receptor blockade following naltrexone: Measurement by 11C-carfentanil pet
E. M. Bednarczyk PharmD, D. Wack MS, M. Haka PhD, Y. Shang PhD, L. Hershey MD, PhD, R. O'Sullivan MD and T. Fullerton PharmD
Clin Pharmacol Ther 77: P26-P26; doi:10.1016/j.clpt.2004.11.099
A randomized double-blind placebo-controlled 10-way crossover study to show that a new zolpidem modified-release formulation improves sleep maintenance compared to standard zolpidem
I. Hindmarch PhD, E. Legangeux, S. Emegbo and A. Nixon
Clin Pharmacol Ther 77: P26-P26; doi:10.1016/j.clpt.2004.11.100
Impact of the CYP2D6 ultra-rapid metabolizer genotype on CIS- and trans-doxepin pharmacokinetics and serotonin concentration in platelets
J.C. Kirchheiner MD, H. B. Henckel MS, L. Franke PhD, I. Meineke PhD, R. Uebelhack MD, I. Roots MD and J. Brockmöller MD
Clin Pharmacol Ther 77: P26-P26; doi:10.1016/j.clpt.2004.11.101
Variability in the pharmacokinetics of R-(-)- and S-(+)-mirtazapine in dependence of the CYP2D6 genotype
J. C. Kirchheiner MD, H. B. Henckel MS, I. Meineke PhD, I. Roots MD and J. Brockmöller MD
Clin Pharmacol Ther 77: P26-P26; doi:10.1016/j.clpt.2004.11.102
Pharmacokinetics and tolerability of atomoxetine in adults of known CYP2D6 phenotype
J. Witcher PhD, A. Long BS, J. M. Sauer PhD, B. Smith PhD and H. Read MD, PhD
Clin Pharmacol Ther 77: P27-P27; doi:10.1016/j.clpt.2004.11.103
Hemodynamic effects of duloxetine at supratherapeutic dosages
M. Derby, L. Zhang, C. Gonzales, J. Chappell, R. Lucas and J. T. Callaghan
Clin Pharmacol Ther 77: P27-P27; doi:10.1016/j.clpt.2004.11.104
Feasibility of assessing differential pharmacodynamic (PD)/adverse events (AE) profiles on CNS agents
A. Moton PharmD, D. Ouellet PhD, R. Morlock PhD, J. Nyberg MS and D. Feltner MD
Clin Pharmacol Ther 77: P27-P27; doi:10.1016/j.clpt.2004.11.105
A randomized double-blind placebo-controlled3-way crossover study investigating psychomotor and cognitive residual effects of a new zolpidem modified-release formulation in healthy volunteers
O. Blin PhD, J. Micallef-Rolle, E. Legangeux and I. Zobouyan
Clin Pharmacol Ther 77: P27-P27; doi:10.1016/j.clpt.2004.11.106
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS-233 SR) in healthy subjects
V. Parks, A. Patat, J. Behrle, V. Parker and J. Decours
Clin Pharmacol Ther 77: P28-P28; doi:10.1016/j.clpt.2004.11.107
Clarithromycin impairs clearance and potentiates clinical effects of trazodone but not of zolpidem
D. J. Greenblatt MD, L. L. von Moltke MD and J. S. Harmatz BA
Clin Pharmacol Ther 77: P28-P28; doi:10.1016/j.clpt.2004.11.108
Child neurodevelopment following treatment for nausea and vomiting of pregnancy with diclectin: A prospective controlled study
I. Nulman MD, H. Illios MA, D. Knittel-Keren BA, M. Barrera PhD and G. Koren MD
Clin Pharmacol Ther 77: P28-P28; doi:10.1016/j.clpt.2004.11.109
Pharmacodynamic effects of opiate receptor antagonism: An agonist challenge study
S. Chalon MD, PhD, J. G. Suico MD, D. Renard PhD, M. K. Carter BS, K. Diringer BS, J. Chavers BS and A. S. Cantrell MS
Clin Pharmacol Ther 77: P28-P28; doi:10.1016/j.clpt.2004.11.110
Age-gender study of SRA-333, a novel 5-HT1A antagonist
A. Patat, V. Parks, S. Raje, A. Plotka and B. Dietrich
Clin Pharmacol Ther 77: P29-P29; doi:10.1016/j.clpt.2004.12.001
Disposition of roflumilast in pediatrics
G. Kearns, S. Szefler, S. Abdel Rahman, G. Lahu, K. Zech and T. Bethke
Clin Pharmacol Ther 77: P29-P29; doi:10.1016/j.clpt.2004.12.002
Breastfeeding women with depression: Maternal and infant well-being
A. Lee MSc, W. Ungar PhD, B. Wang BSc, M. Romach MD and S. Ito MD
Clin Pharmacol Ther 77: P29-P29; doi:10.1016/j.clpt.2004.12.003
The reproductive effects of beta interferon therapy for multiple sclerosis
R. Boskovic MD, R. Wade BSc. and G. Koren MD
Clin Pharmacol Ther 77: P29-P29; doi:10.1016/j.clpt.2004.12.004
Pregnancy outcome following gestational exposure to montelukast: A prospective cotrolled study
M. Sarkar BSc Hon and G. Koren MD
Clin Pharmacol Ther 77: P30-P30; doi:10.1016/j.clpt.2004.12.005
Pharmacokinetics (PK) and absolute bioavailability (F) of linezolid (L) in cystic fibrosis (CF) patients (PTS)
M. Reed PharmD, M. Konstan MD, M. O'Riordan MS and J. Blumer PhD, MD
Clin Pharmacol Ther 77: P30-P30; doi:10.1016/j.clpt.2004.12.006
Patterns of drug utilization in a neonatal intensive care unit
I. Warrier MD, W. Du PhD, G. Natarajan MD, V. Salari PhD and J. V. Aranda MD, PhD
Clin Pharmacol Ther 77: P30-P30; doi:10.1016/j.clpt.2004.12.007
Pharmacokinetics of rifapentine in children
M. J. Blake PhD, MD, S. M. Abdel-Rahman PharmD, R. F. Jacobs MD, N. K. Lowery RN and G. L. Kearns PharmD, PhD
Clin Pharmacol Ther 77: P30-P30; doi:10.1016/j.clpt.2004.12.008
Buspirone pharmacokinetics in autistic children
D. Edwards PharmD, D. C. Chugani PhD, H. T. Chugani MD, J. Chehab, M. Malian and J. V. Aranda MD, PhD
Clin Pharmacol Ther 77: P31-P31; doi:10.1016/j.clpt.2004.12.009
Effect of MDR1 genotype (G2677T) on the disposition of ciprofloxacin in adults
J. C. Gorski PhD, J. L. Renbarger MD, R. Vuppalanchi MD, M. Miller PhD, R. E. Galinsky PharmD and S. D. Hall PhD
Clin Pharmacol Ther 77: P31-P31; doi:10.1016/j.clpt.2004.12.010
Characterization of P-glycoprotein inhibition at the blood brain barrier by ketoconazole and quinidine using the central pharmacodynamics of loperamide as an indicator of brain distribution
T. Fullerton PharmD, M. Bednar MD, PhD, P. Raava MS, J. Legg BS, D. Hoelscher MD, D. Eckols BS and M. Gibbs PhD
Clin Pharmacol Ther 77: P31-P31; doi:10.1016/j.clpt.2004.12.011
Projection of doses for QT-prolongation studies based on modeling of the worst-case inhibition of CYP3A
J. Y. Chien PhD, S. D. Hall PhD and S. A. Wrighton PhD
Clin Pharmacol Ther 77: P31-P31; doi:10.1016/j.clpt.2004.12.012
Population pharmacokinetic modeling of the interaction between the P-glycoprotein inhibitor PSC-833 and mitoxantrone in pediatric leukemia patients
S. Kshirsagar PhD, T. Blaschke MD, D. Verotta PhD, N. Lacayo MD, G. Dahl MD and B. Sikic
Clin Pharmacol Ther 77: P32-P32; doi:10.1016/j.clpt.2004.12.013
Pharmacokinetic interaction between voriconazole and methadone at steady state in methadone patients
P. Liu PhD, G. Foster PhD, R. Labadie MPH, E. Somoza MD, PhD and A. Sharma PhD
Clin Pharmacol Ther 77: P32-P32; doi:10.1016/j.clpt.2004.12.014
Optimizing plasma sampling of oral (PO) midazolam (MDZ) as a biomarker for CYP3A activity
L. S. Lee PharmD, J. S. Bertino Jr. PharmD and A. N. Nafziger MD, MHS
Clin Pharmacol Ther 77: P32-P32; doi:10.1016/j.clpt.2004.12.015
The ratio of 1-hydroxymidazolam (1-OH MDZ) to midazolam (MDZ) plasma concentrations is not an accurate measurement for CYP3A activity when using oral (PO) MDZ
L. S. Lee PharmD, A. N. Nafziger MD, MHS and J. S. Bertino Jr. PharmD
Clin Pharmacol Ther 77: P32-P32; doi:10.1016/j.clpt.2004.12.016
Effects of posture (P) induced changes in hepatic blood flow (HBF) and plasma protein binding (PB) on the clearance (CL) of the intravenous (IV) cytochrome P450 3A (CYP3A) biomarker midazolam (MDZ)
J. D. Ma PharmD, A. N. Nafziger MD, MHS, W. Mylott BS, D. B. Haughey PharmD, PhD, M. L. Rocci PhD and J. S. Bertino PharmD
Clin Pharmacol Ther 77: P33-P33; doi:10.1016/j.clpt.2004.12.017
A multiphasic absorption model for characterizing single dose pharmacokinetics of divalproex-ER in healthy subjects
S. Dutta PhD, R. C. Reed PharmD and J. H. Cavanaugh PhD, MD
Clin Pharmacol Ther 77: P33-P33; doi:10.1016/j.clpt.2004.12.018
Rationale for fixed dosing of pertuzumab by population pharmacokinetic (POP PK) modeling
C. Ng PharmD, PhD, B. L. Lum PharmD, S. Kelsey MD, V. Hersberger-Gimenez MD and D.E. Allison BS
Clin Pharmacol Ther 77: P33-P33; doi:10.1016/j.clpt.2004.12.019
Pharmacodynamics of promethazine in human subjects
K. Gatlin PharmD, J. L. Boyd PhD, Z. Wang PhD, H. Das MPH and L. Putcha PhD
Clin Pharmacol Ther 77: P33-P33; doi:10.1016/j.clpt.2004.12.020
Genetic polymorphisms in the glucuronosyltransferases 1A1, 1A8 and 1A9 in relation to pharmacokinetics of furosemide
D. Sehrt MD, S. Vormfelde MD, M. Toliat PhD, P. Nürnberg PhD, M. Schirmer MD and J. Brockmöller MD
Clin Pharmacol Ther 77: P34-P34; doi:10.1016/j.clpt.2004.12.021
Effect of ketoconazole on the temsirolimus pharmacokinetic profile in healthy subjects
C. Shu, M. Afsharvand, D. Raible and H. Zhou
Clin Pharmacol Ther 77: P34-P34; doi:10.1016/j.clpt.2004.12.022
Differential regulation of basolateral and canalicular transporter expression in rat liver in chronic renal failure
B. Holzer, B. Stieger PhD, G. Folkers PhD, P. J. Meier MD and K. Fattinger MD
Clin Pharmacol Ther 77: P34-P34; doi:10.1016/j.clpt.2004.12.023
Changes in CYP450 enzyme activity over time following liver transplantation
S. Liu MD, R. Frye PharmD, PhD, R. Branch MD, R. Venkataramanan PhD, J. Fung MD, PhD and G. Burckart PharmD
Clin Pharmacol Ther 77: P34-P34; doi:10.1016/j.clpt.2004.12.024
Dose dependent inhibition of midazolam elimination by ketoconazole: Effect of CYP3A5 genotype
A. Lucksiri PharmD, R. Vuppalanchi MD, J. K. Hilligoss LPN, M. A. Hamman BS, L. Li PhD, J. Y. Chien PhD, S. Huang PhD and S. D. Hall PhD
Clin Pharmacol Ther 77: P35-P35; doi:10.1016/j.clpt.2004.12.025
Effect of St. John's Wort administration on CYP2C8 mediated rosiglitazone metabolism
M. W. Hruska PharmD, J. A. Cheong MD, T. Y. Langaee MSPH, PhD and R. F. Frye PharmD, PhD
Clin Pharmacol Ther 77: P35-P35; doi:10.1016/j.clpt.2004.12.026
A five-probe drug cocktail for phenotyping of CYP isozymes with "high-throughput" LC-MS method
O. Q. Yin PhD, B. Tomlinson and M. S. Chow
Clin Pharmacol Ther 77: P35-P35; doi:10.1016/j.clpt.2004.12.027
Population variability of CYP2C9 activity in caucasians: Effects of genotype versus enzyme induction
J. Brockmöller MD, S. Vormfelde MD, S. Bauer and J. Kirchheiner
Clin Pharmacol Ther 77: P35-P35; doi:10.1016/j.clpt.2004.12.028
Effect of CYP2C8 genotype on rosiglitazone pharmacokinetics
M. W. Hruska PharmD, J. A. Cheong MD, J. A. Amico MD, T. Y. Langaee MSPH, PhD and R. F. Frye PharmD, PhD
Clin Pharmacol Ther 77: P36-P36; doi:10.1016/j.clpt.2004.12.029
Effect of goldenseal, black cohosh, kava kava, and valerian on human cytochrome p450 1A2, 2D6, 2E1, and 3A4 phenotypes
B. J. Gurley PhD, S. F. Gardner PharmD, D. K. Williams PhD, W. B. Gentry MD, M. A. Hubbard MS, I. A. Khan PhD and A. Shah PhD
Clin Pharmacol Ther 77: P36-P36; doi:10.1016/j.clpt.2004.12.030
Induction of CYP3A by St. Johns Wort (SJW) depends on hyperforin (HYF) dose
S. C. Mueller MD, J. Majcher-Peszynska MD, S. Klammt MD, B. Uehleke MD, PhD, W. Miekisch PhD, G. Kundt PhD and B. Drewelow MD
Clin Pharmacol Ther 77: P36-P36; doi:10.1016/j.clpt.2004.12.031
In vitro glucuronidation of prednisone
F. Innocenti MD, PhD, A. Yoder Graber BA, J. Ramirez MS and M.J. Ratain MD
Clin Pharmacol Ther 77: P36-P36; doi:10.1016/j.clpt.2004.12.032
Evaluation of body-surface area based dosing of cisplatin in patients with extreme BSA values
W. J. Loos PhD, F. E. de Jongh MD, PhD, A. Sparreboom PhD, I. M. van den Bos, G. Stoter MD, PhD, K. Nooter PhD and J. Verweij MD, PhD
Clin Pharmacol Ther 77: P37-P37; doi:10.1016/j.clpt.2004.12.033
Pharmacokinetics of intravenous d- and l-methamphetamine in healthy volunteers
N. Uemura MD, PhD, D. Harris MD, R. P. Nath MD, E. Fernandez MD, P. Jacob lll PhD, E. T. Everhart PhD, R. T. Jones MD and J. Mendelson MD
Clin Pharmacol Ther 77: P37-P37; doi:10.1016/j.clpt.2004.12.034
Using a compartmental approach to estimate the absolute bioavailability of erlotinib, a small molecule inhibitor of the epidermal growth factor receptor (EGFR)
J. Lu PhD, B. Lum PharmD, S. Eppler MS, M. Hamilton PhD, A. Rakhit PhD and P. Frohna PKPDS
Clin Pharmacol Ther 77: P37-P37; doi:10.1016/j.clpt.2004.12.035
Pharmacokinetic evaluation of combined duloxetine and fluvoxamine dosing in CYP2D6 poor metabolizers
D. Small, C. Loghin, R. Lucas, M. P. Knadler, L. Zhang, J. Chappell, R. Bergstrom and J. T. Callaghan
Clin Pharmacol Ther 77: P37-P37; doi:10.1016/j.clpt.2004.12.036
Effects of varying degrees of renal impairment on the pharmacokinetic disposition of nebivolol
A. A. Shaw PhD, S. Liu MS, L. F. Zachwieja BS, T. Eddy BS, C. M. Donnelly MS and M. Y. Huang PhD
Clin Pharmacol Ther 77: P38-P38; doi:10.1016/j.clpt.2004.12.037
Effect of chronic administration of fluoxetine on the pharmacokinetics of nebivolol
A. A. Shaw PhD, S. Liu MS, L. F. Zachwieja BS, C. M. Donnelly MS and M. Y. Huang PhD
Clin Pharmacol Ther 77: P38-P38; doi:10.1016/j.clpt.2004.12.038
Lack of interaction between R483, a novel peroxisome proliferator-activated receptor gamma agonist, and drugs metabolized by CYP2C9 and CYP2C19
C. Weber PhD, B. Kuhn BSc, B. Fotteler MSc and C. Funk PhD
Clin Pharmacol Ther 77: P38-P38; doi:10.1016/j.clpt.2004.12.039
Bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis
L. Bi MS, K. M. Huynh, S. Louie PharmD, N. Hoem PhD, J. Kriengkauykiat PharmD, M. Gill PharmD and P. Beringer PharmD
Clin Pharmacol Ther 77: P38-P38; doi:10.1016/j.clpt.2004.12.040
Tariquidar (TAR, XR-9576) selectively inhibits P-glycoprotein (P-gp) in t-lymphocytes compared to that in the blood-brain barrier (BBB)
M. Muszkat MD, D. Kurnik MD, G. G. Sofowora MD, J. P. Donahue PhD, G. R. Wilkinson PhD, D.Sc. and A. J. Wood MD
Clin Pharmacol Ther 77: P39-P39; doi:10.1016/j.clpt.2004.12.041
Population pharmacokinetic profile of montelukast in children aged 3 to 6 months with bronchiolitis
B. Knorr MD, L. Maganti PhD, R. Ramakrishnan PhD, P. Larson MS, C. A. Tozzi PhD and T. F. Reiss MD
Clin Pharmacol Ther 77: P39-P39; doi:10.1016/j.clpt.2004.12.042
Single-dose pharmacokinetics and anticoagulant activity of warfarin is unaffected by nebivolol in healthy volunteers
T.E. Lawrence PhD, S. Liu MS, T. M. Bland PhD, S. W. Chervenick PhD, M. Y. Huang PhD and R. J. Rackley PhD
Clin Pharmacol Ther 77: P39-P39; doi:10.1016/j.clpt.2004.12.043
Propofol elimination in human breast milk
M. J. Avram PhD, M. Nitsun MD, J. W. Szokol MD, J. Saleh MD, G. S. Murphy MD, J. S. Vender MD and K. Raikoff MS
Clin Pharmacol Ther 77: P39-P39; doi:10.1016/j.clpt.2004.12.044
Pharmacokinetic interaction between voriconazole and ritonavir at steady state in healthy subjects
P. Liu PhD, G. Foster PhD, R. Labadie MPH, M. J. Allison MD and A. Sharma PhD
Clin Pharmacol Ther 77: P40-P40; doi:10.1016/j.clpt.2004.12.045
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects
P. Liu PhD, G. Foster PhD, R. Labadie MPH, M. J. Gutierrez MD and A. Sharma PhD
Clin Pharmacol Ther 77: P40-P40; doi:10.1016/j.clpt.2004.12.046
Prospective dose prediction for FXa inhibitor otamixaban (OTAM) using PK/PD simulations accounting for non-dose proportional plasma exposure
A. J. Paccaly PharmD, A. Frick PhD and S. Rohatagi PhD
Clin Pharmacol Ther 77: P40-P40; doi:10.1016/j.clpt.2004.12.047
Effects of hepatic impairment on the pharmacokinetic disposition of nebivolol: A dual acting nitric oxide modulating/ cardioselective beta1-antagonist
A. A. Shaw PhD, S. Liu MS, H.C. Tu MS, S. W. Chervenick PhD, T. Vukic-Bugarski MD and M. Y. Huang PhD
Clin Pharmacol Ther 77: P41-P41; doi:10.1016/j.clpt.2004.12.048
Pharmacokinetic model of zidovudine and its glucuronide metabolite in pregnancy
A. Altincatal BS, R. MacArthur PharmD and M. Garland MD
Clin Pharmacol Ther 77: P41-P41; doi:10.1016/j.clpt.2004.12.049
Clinically unimportant pharmacokinetic drug interaction between fluvoxamine and single doses of caffeine
K. E. Culm-Merdek PhD, L. L. von Moltke MD, J. S. Harmatz and D. J. Greenblatt MD
Clin Pharmacol Ther 77: P41-P41; doi:10.1016/j.clpt.2004.12.050
The effect of folic acid (FA) supplumentation on warfarin (WAR) dose requirement and the formation clearance of (S)-7' OH-warfarin
M. Muszkat MD, O. Bialer, L. Adar MSc, S. Blotnick PhD and Y. Caraco MD
Clin Pharmacol Ther 77: P41-P41; doi:10.1016/j.clpt.2004.12.051
Optimal multi-drug PK sampling strategies (OSS) for efavirenz (EFV) & indinavir (IDV)
Q. Ma, A. Forrest, S. Rosenkranz, M. F. Para, E. Adams, K. E. Yarasheski, R. C. Reichman and G. D. Morse
Clin Pharmacol Ther 77: P42-P42; doi:10.1016/j.clpt.2004.12.052
Single and multiple dose pharmacokinetics of long-acting injectable naltrexone
R. Turncliff PhD, J. Dunbar PharmD, Q. Dong PhD, J. Oliva, K. Lasseter MD and B. Silverman MD
Clin Pharmacol Ther 77: P42-P42; doi:10.1016/j.clpt.2004.12.053
Effect of gender, race and genotype on interpatient variability in the pharmacokinetics of efavirenz
P. W. Schenk, D. M. Burger, I. P. van der Heiden, C. L. la Porte, M. E. van der Ende, P. Groeneveld, C. Richter, P. P. Koopmans, F. P. Kroon, H. Sprenger, J. Lindemans and R. N. van Schaik
Clin Pharmacol Ther 77: P42-P42; doi:10.1016/j.clpt.2004.12.054
Stimulation of P-GP mediated transport & expression by flutamide in vitro
K. M. Bertelsen BS, L. L. von Moltke MD and D. J. Greenblatt MD
Clin Pharmacol Ther 77: P42-P42; doi:10.1016/j.clpt.2004.12.055
Pharmacokinetics and pharmacodynamics of infliximab, an anti-tumor necrosis factor-alpha monoclonal antibody, following single subcutaneous administrations in rheumatoid arthritis patients
Y.W. Zhu PhD, C. Pendley PhD, D. Sisco, R. Westhovens MD, PhD, P. Durez MD, E. Bouman-Thio MD, B. van Hartingsveldt, D. E. Everitt MD and M. A. Graham PhD
Clin Pharmacol Ther 77: P43-P43; doi:10.1016/j.clpt.2004.12.056
Predict receptor occupancy for compound A at receptor R2 based on its occupancy at receptor R1
S. Mu PhD, S. Mitchell PhD and W. Ebling
Clin Pharmacol Ther 77: P43-P43; doi:10.1016/j.clpt.2004.12.057
Population pharmacokinetic analysis of rimonabant in healthy subjects
G.M. Ferron PharmD, PhD, M. Grandison PhD and G. Lockwood PhD
Clin Pharmacol Ther 77: P43-P43; doi:10.1016/j.clpt.2004.12.058
Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects
R. Khosravan PhD, K. Erdman BS, L. Vernillet PharmD, PhD, J. T. Wu PhD, N. Joseph-Ridge MD, S. Umeda PhD and D. Mulford PhD
Clin Pharmacol Ther 77: P43-P43; doi:10.1016/j.clpt.2004.12.059
Clinical pharmacokinetics of tanaproget, a nonsteroidal progesterone receptor (PR) agonist, in healthy cycling women during 28 days of administration
J. Bapst PharmD, G. Orczyk MD, PhD and J. Ermer MS
Clin Pharmacol Ther 77: P44-P44; doi:10.1016/j.clpt.2004.12.060
Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers
Y. Chen PhD, L. Robertson RN, J. Carlson PharmD and N. Kivel MD
Clin Pharmacol Ther 77: P44-P44; doi:10.1016/j.clpt.2004.12.061
Pharmacokinetic profile of a new modified-release formulation of zolpidem designed to improve sleep maintenance
E. Weinling PhD, S. McDougall, F. Andreé, C. Dubruc, G. Bianchetti and E. Krupka
Clin Pharmacol Ther 77: P44-P44; doi:10.1016/j.clpt.2004.12.062
Safety, pharmacokinetics (ZCASEPk) and pharmacodynamics (PD) of ascending single oral doses of sustained-release desvenlafaxine succinate (DVS-SR) in healthy subjects
V. Parks BSc(hons), A. Patat MD, PhD, J. A. Behrle MS, S. M. Troy MS and J. H. Decours MD
Clin Pharmacol Ther 77: P44-P44; doi:10.1016/j.clpt.2004.12.063
Evaluation of the effect of lasofoxifene (LASO) on the pharmacokinetics (PK) of digoxin
D. Roman MD, C. Bramson MD, D. Ouellet PhD, E. Randinitis PhD and M. J. Gardner PhD
Clin Pharmacol Ther 77: P45-P45; doi:10.1016/j.clpt.2004.12.064
A pilot study to assess simultaneous administration of oral midazolam (MDZ) and fexofenadine (FEX) for the evaluation of cytochrome (CYP) 3A4 and P-glycoprotein (P-GP) activities
M. Garrett BS, J. Smeraglia MS, X. Lin PhD, L. Tan MD and J. Tran PharmD
Clin Pharmacol Ther 77: P45-P45; doi:10.1016/j.clpt.2004.12.065
Pharmacokinetics (PK) of multiple oral doses of desloratadine (DCL) and fexofenadine (FEX) in a population of healthy adults identified phenotypically as desloratadine slow metabolizers (DSMS)
W. Kraft MD, R. A. Blum, G. S. Frick, C. Vitow, J. A. Stewart and S. J. Kovacs
Clin Pharmacol Ther 77: P45-P45; doi:10.1016/j.clpt.2004.12.066
Distribution of 3H-domperidone, a P-glycoprotein (P-gp) substrate, in heart structures and whole-body tissues of MDR1A (-/-) mice
L. Couture, L. Nguyen PhD, L. Tao PhD, J. A. Nash PhD and J. Turgeon PhD
Clin Pharmacol Ther 77: P46-P46; doi:10.1016/j.clpt.2004.12.067
Effects of infant formula, cow milk and human milk on drug metabolizing enzymes
H. Xu, R. Rajesan, R. B. Kim, S. A. Kliewer, B. Lonnerdal, P. A. Harper, M. Ho, J. W. Yun, J. Hutson and S. Ito
Clin Pharmacol Ther 77: P46-P46; doi:10.1016/j.clpt.2004.12.068
No effect of amoxicillin, doxycycline, and ciprofloxacin on the pharmacokinetics and pharmacodynamics of ximelagatran
H. Dorani, K. Schützer, T. Sarich, U. Wall, L. Ohlsson and U. Eriksson
Clin Pharmacol Ther 77: P46-P46; doi:10.1016/j.clpt.2004.12.069
Lack of pharmacokinetic interaction between nebivolol and spironolactone
T. L. Morton PhD, H. C. Tu MS, S. Liu MS, S. W. Chervenick PhD, R. J. Rackley PhD and M. Y. Huang PhD
Clin Pharmacol Ther 77: P46-P46; doi:10.1016/j.clpt.2004.12.070
The absolute bioavailability of an oral sustained-release formulation of desvenlafaxine succinate in healthy subjects
V. D. Parker PhD, L. S. Richards MA, A. I. Nichols PhD, J. A. Behrle MS and R. J. Fruncillo MD, PhD
Clin Pharmacol Ther 77: P47-P47; doi:10.1016/j.clpt.2004.12.071
A study of the effects of lasofoxifene (LASO) on the pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin
D. Ouellet PhD, C. Bramson MD, S. Carvajal-Gonzalez PhD, A. E. Remmers PhD, D. Roman MD, E. Randinitis PhD and M. J. Gardner PhD
Clin Pharmacol Ther 77: P47-P47; doi:10.1016/j.clpt.2004.12.072
Lack of effect of aprepitant on the pharmacokinetics of hydrodolasetron in CYP2D6 extensive and poor metabolizers
X. Li PhD, E. Pequignot MS, D. Panebianco MS, A. Majumdar PhD, D. Selverian, L. Rosen MD, PhD and K. Petty MD, PhD
Clin Pharmacol Ther 77: P47-P47; doi:10.1016/j.clpt.2004.12.073
Disposition of desloratadine in healthy volunteers
L. Reyderman PhD, R. Ramanathan PhD, S. Chowdhury PhD, K. Alton MS, P. Statkevich PhD and M. Wirth PhD
Clin Pharmacol Ther 77: P48-P48; doi:10.1016/j.clpt.2004.12.074
Effect of Ginkgo on CYP2C9: In vitro and in vivo studies
D. J. Greenblatt MD, L. L. von Moltke MD, E. S. Perloff PhD, Y. Luo, J. S. Harmatz BA, E. Bedir PhD, I. A. Khan PhD and P. Goldman MD
Clin Pharmacol Ther 77: P48-P48; doi:10.1016/j.clpt.2004.12.075
Population pharmacokinetic model of sedative doses of GPI15715 and propofol liberated from GPI15715
E. Gibiansky PhD, L. Gibiansky PhD and J. Enriquez MD
Clin Pharmacol Ther 77: P48-P48; doi:10.1016/j.clpt.2004.12.076
Pharmacokinetic profile of parecoxib sodium, an injectable prodrug of the Cox-2-selective inhibitor, valdecoxib
S. Krishnaswami PhD
Clin Pharmacol Ther 77: P48-P48; doi:10.1016/j.clpt.2004.12.077
Assessment of milk thistle and black cohosh supplementation on digoxin pharmacokinetics
B. J. Gurley PhD, M. A. Hubbard MS, G. Barone MD, Y. Tong MS, D. K. Williams PhD, J. Carrier PhD and I. Khan PhD
Clin Pharmacol Ther 77: P49-P49; doi:10.1016/j.clpt.2004.12.078
Inhibitory effect of stiripentol on clobazam metabolism by cDNA-expressed human CYP
A. Tran PharmD, PhD, C. Giraud, E. Rey PharmD, J. Vincent PharmD, J. Treluyer MD, PhD and G. Pons MD, PhD
Clin Pharmacol Ther 77: P49-P49; doi:10.1016/j.clpt.2004.12.079
Alvimopan pharmacokinetics (PK) & pharmacodynamics (PD) in patients with chronic constipation (CC)
V. D. Schmith PhD, W. Garnett PharmD, W. H. Barr PharmD, PhD, D. Kelleher PhD, M. Young PhD, G. Sanderlin, S. Coots, A. Agyemang and G. Dukes PharmD
Clin Pharmacol Ther 77: P49-P49; doi:10.1016/j.clpt.2004.12.080
The bioequivalence of oral administration of telithromycin tablets crushed versus swallowed whole in healthy adult subjects
C. L. Lippert PhD, S. Gbenado MS, C. Qiu PhD, B. Lavin MD and S. J. Kovacs PharmD
Clin Pharmacol Ther 77: P49-P49; doi:10.1016/j.clpt.2004.12.081
A population pharmacokinetic model for pentadecanoic acid (PA) and triheptadecanoic acid (THA) exposure following administration of a malabsorption blood test (MBT) to quantify steatorrhea
J. Mondick, J. Barrett, J. Schall, M. Mascarenhas and V. Stallings
Clin Pharmacol Ther 77: P50-P50; doi:10.1016/j.clpt.2004.12.082
Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects
R. Khosravan PhD, B. Grabowski BA, J. T. Wu PhD, N. Joseph-Ridge MD and L. Vernillet PharmD, PhD
Clin Pharmacol Ther 77: P50-P50; doi:10.1016/j.clpt.2004.12.083
Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects
R. Khosravan PhD, M. Kukulka BS, J. T. Wu PhD, N. Joseph-Ridge MD and L. Vernillet PharmD, PhD
Clin Pharmacol Ther 77: P50-P50; doi:10.1016/j.clpt.2004.12.084
Pharmacokinetics of mosapride citrate in patients with gastrectomy
Y. Kumagai, T. Fujita MD, M. Ozaki MD, Y. Ohtani MD and M. Majima MD
Clin Pharmacol Ther 77: P51-P51; doi:10.1016/j.clpt.2004.12.085
Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of WAY-195725
H. Zhou PhD, A. Diehl MPH, S. Waldman MD, PhD, M. Shen PhD, J. Clark PhD and D. Raible MD
Clin Pharmacol Ther 77: P51-P51; doi:10.1016/j.clpt.2004.12.086
Pharmacokinetics and analgesic effects of intravenous buprenorphine
M. Escher MD, Y. Daali, J. Chabert, G. Hopfgartner, P. Dayer and J. Desmeules
Clin Pharmacol Ther 77: P51-P51; doi:10.1016/j.clpt.2004.12.087
Patients' criteria for meaningful relief to determine onset of action
B. P. Schachtel MD, K. M. Sanner RN, N. A. Meskin BS and M. Bey RN
Clin Pharmacol Ther 77: P51-P51; doi:10.1016/j.clpt.2004.12.088
How 'fast' is over-the-counter (OTC) pain relief?
B. P. Schachtel MD, N. A. Meskin BS and K. M. Sanner RN
Clin Pharmacol Ther 77: P52-P52; doi:10.1016/j.clpt.2004.12.090
Validation of a new outpatient orthopedic pain model utilizing "Hammertoe" surgery: Statistical separation of an opioid combination and a Cox -2 inhibitor from placebo
P. J. Desjardins DMD, PhD, N. Cantu MSN, RN, FNP, P. M. Black BS, MS and S. E. Daniels
Clin Pharmacol Ther 77: P52-P52; doi:10.1016/j.clpt.2004.12.089
Efficacy and tolerability of the cyclooxygenase-2 inhibitor L-791,515 compared with ibuprofen in patients with postoperative dental pain
J. I. Schwartz PharmD, MPH, J. R. Fricke Jr. DDS, MSD, P. N. Kotey PhD, D. L. Ebel BS, J. A. Wagner MD, PhD and K. M. Gottesdiener MD
Clin Pharmacol Ther 77: P52-P52; doi:10.1016/j.clpt.2004.12.091
Local periodontal cytokine (tumor necrosis factor) induction by lipopolysaccharide in the mice air pouch and its relationship to the febrile response
L. G. Branco PhD and V. P. Navarro
Clin Pharmacol Ther 77: P52-P52; doi:10.1016/j.clpt.2004.12.092
Castration reduces human platelet TXA2 receptor density and aggregability
A. A. Ajayi MD, PhD and P. V. Halushka PhD, MD
Clin Pharmacol Ther 77: P53-P53; doi:10.1016/j.clpt.2004.12.093
Pharmacodynamics (PD) of clopidogrel in patients with acute coronary syndromes undergoing percutaneous interventions (PCI)
I. Fuchs MD, M. Frossard MD, A. Laggner MD, A. Spiel MD, E. Wohlschläger MD and B. Jilma MD
Clin Pharmacol Ther 77: P53-P53; doi:10.1016/j.clpt.2004.12.094
Efficacy and safety of controlled-release isosorbide-5-mononitrate for patients with stable effort angina pectoris: A randomized, double-blind, placebo-controlled study
K. Shimada MD, S. Sunayama MD, K. Nakazato MD, H. Satoh MD and H. Daida MD, PhD
Clin Pharmacol Ther 77: P53-P53; doi:10.1016/j.clpt.2004.12.095
B2-mediated glucose production during carvedilol and metoprolol titration in heart failure
K. I. Cheang, O. Carter, J. Zebrack, M. Munger and E. M. Gilbert
Clin Pharmacol Ther 77: P54-P54; doi:10.1016/j.clpt.2004.12.096
Deficit in the sulfonylurea receptor KATP channel complex compromises the metabolic benefit of exercise training resulting in cardiac deficits
G. C. Kane MB BCh BAO, A. Behfar, S. Yamada, C. Perez-Terzic, P. O'Cochlain, S. Reyes, P. P. Dzeja, T. Miki, S. Seino and A. Terzic
Clin Pharmacol Ther 77: P54-P54; doi:10.1016/j.clpt.2004.12.097
Clopidogrel use in children
Y. Finkelstein MD, L. Nurmohamed, L. Benson MD and G. Koren MD
Clin Pharmacol Ther 77: P54-P54; doi:10.1016/j.clpt.2004.12.098
Association between CYP3A5 and blood pressure in nigerian males
K. A. Neville, O. E. Ayaji, C. L. Holland, T. C. Skaar and S. D. Hall
Clin Pharmacol Ther 77: P55-P55; doi:10.1016/j.clpt.2004.12.099
Propranolol for neurocardiogenic syncope with sympathoadrenal imbalance
B. Eldadah, S. Pechnik, C. Holmes and D. S. Goldstein
Clin Pharmacol Ther 77: P55-P55; doi:10.1016/j.clpt.2004.12.100
Consistent inhibition of acid output with repeated dosing of AZD0865 in rats
B. Holstein PhD, M. Florentzson BSc and K. Andersson PhD
Clin Pharmacol Ther 77: P55-P55; doi:10.1016/j.clpt.2004.12.101
Pharmacokinetics and tolerability of a novel long acting glucagon-like-peptide-1 analog CJC-1131
A. A. van Vliet MD, PhD, R. G. Tiessen MD, PhD, M. H. Kruizinga, J. F. Dreyfus MD, PhD and P. H. Guivarch MD, PhD
Clin Pharmacol Ther 77: P56-P56; doi:10.1016/j.clpt.2004.12.102
The pharmacokinetics and pharmacodynamics of 17-d-norgestimate and ethinyl estradiol alone and in the presence of cilansetron 2 mg TID, in healthy females
T. L. ZumBrunnen PharmD, P. Boon PhD, J. Chang PhD, M. deVries PhD, PharmD and J. J. Brennan PhD
Clin Pharmacol Ther 77: P56-P56; doi:10.1016/j.clpt.2004.12.103
Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes
Y. L. He PhD, A. Balch PhD, J. Campestrini PhD, G. J. Rivere PhD, D. Serra BS, P. Prasad PhD and M. Ligueros-Saylan MD
Clin Pharmacol Ther 77: P56-P56; doi:10.1016/j.clpt.2004.12.104
Lack of effect of LAF237 on C-peptide clearance in patients with type 2 diabetes
Y. L. He PhD, A. Horowitz PhD, C. Watson PhD, J. Foley PhD, W. Sallas PhD and M. Ligueros-Saylan MD
Clin Pharmacol Ther 77: P56-P56; doi:10.1016/j.clpt.2004.12.105
Evaluation of pharmacokinetic characteristics of a novel anti-IBD drug, DA-6034, in healthy volunteers
K. S. Lim MD, J. Y. Chung MD, J. R. Kim MD, H. R. Jung RPh, J. Y. Cho PhD, K. S. Yu MD, PhD, M. W. Son PhD, J. Y. Chung, I. J. Jang MD, PhD and S. G. Shin MD, PhD
Clin Pharmacol Ther 77: P57-P57; doi:10.1016/j.clpt.2004.12.106
Impact of genetic polymorphisms in the gene coding for sodium potassium dichloride cotransporter (NKCC2) and serum glucocorticoid kinase (SGK1) for pharmacodynamics of furosemide
D. Sehrt MD, S. Vormfelde MD, M. Toliat PhD, P. Nürnberg PhD, M. Schirmer MD and J. Brockmöller MD
Clin Pharmacol Ther 77: P57-P57; doi:10.1016/j.clpt.2004.12.107
The prevalence of CYP2C9, 2J2, and soluble epoxide hydrolase (SEH) polymorphisms in African-Americans (AA) on hemodialysis (HD)
A. W. Dreisbach MD, S. Japa PhD, A. Sigel BS, M. B. Parenti BSRN, A. E. Hess BA, S. Srinnouanprachanh BS, F. M. Farin MD, A.E. Rettie PhD and J. J. Lertora MD, PhD
Clin Pharmacol Ther 77: P57-P57; doi:10.1016/j.clpt.2004.12.108
Modeling circadian rhythm of diastolic blood pressure in hypertensive patients using 24-hour ambulatory blood pressure monitoring
H. Lee MD, PhD, D. Yim MD, PhD, B. Green PharmD, PhD and C. Peck MD, PhD(hon.)
Clin Pharmacol Ther 77: P57-P57; doi:10.1016/j.clpt.2004.12.109
Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydolase (SEH) polymorphims in African-Americans with hypertension (HTN)
A.W. Dreisbach MD, S. Japa PhD, A. Sigel BS, M. B. Parenti BSRN, R. Vargas BS, S. Srinnouanprachanh BS, F. M. Farin MD, A. E. Rettie PhD and J. J. Lertora MD, PhD
Clin Pharmacol Ther 77: P58-P58; doi:10.1016/j.clpt.2004.12.110
Inflammatory parameters in renal transplant patients before and after P2Y12 inhibition
J. Graff MD
Clin Pharmacol Ther 77: P58-P58; doi:10.1016/j.clpt.2004.12.111
Effects of short IV infusions of DT-009, a novel adenosine (A1-) receptor agonist, on renal function in healthy subjects
J. Venitz MD, PhD, D. Sica MD, R. Townsend RN, PhD and M. Dessimoz BS
Clin Pharmacol Ther 77: P58-P58; doi:10.1016/j.clpt.2004.12.112
Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist
A. Lane PhD, D. Kleinermanns MD, S. Bryson PhD, J. Lee, H. Tan PhD and Y. Chi
Clin Pharmacol Ther 77: P58-P58; doi:10.1016/j.clpt.2004.12.113
Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist
A. Lane PhD, E. Engmann MB ChB, S. Bryson PhD, J. Lee, H. Tan PhD and Y. Chi
Clin Pharmacol Ther 77: P59-P59; doi:10.1016/j.clpt.2004.12.114
Population pharmacokinetics of abacavir in children
V. Jullien PharmD, S. Urien PhD, H. Chappuy MD, J. Dimet PharmD, E. Rey PharmD, G. Pons PhD, S. Blanche PhD and J. Treluyer PhD
Clin Pharmacol Ther 77: P59-P59; doi:10.1016/j.clpt.2004.12.115
Pharmacokinetics (PK) and pharmacodynamics (PD) of enfuvirtide in HIV-1-infected children over 24 weeks of treatment
X. Zhang PhD, T. Lin PharmD, A. Dorr PhD, A. Bertasso MS, C. Evans RGN, L. Rowell MS, S. Kolis MS and W. Veloso BS
Clin Pharmacol Ther 77: P59-P59; doi:10.1016/j.clpt.2004.12.116
Efficacy of methylene blue and artesunate as combination antimalarial therapy in a rhesus monkey model of uncomplicated blood-stage malaria
T. L. Barker MD, MPH, M. Gettayacamin DVM, P. Hansukjariya, Y. Van Gessel DVM, V. Melendez PhD, P. Teja-Isavadharm PhD, J. Vennerstrom PhD, R. S. Miller MD and C. K. Ohrt MD, MPH
Clin Pharmacol Ther 77: P59-P59; doi:10.1016/j.clpt.2004.12.117
Systemic pharmacokinetics of rifaximin (RFX) in subjects with shigellosis
C. B. Trapnell MD, D. N. Taylor MD, C. Montgomery BA, CCRA, D. Bettenhausen PharmD, R. Haake PhD and H. S. Pentikis PhD
Clin Pharmacol Ther 77: P60-P60; doi:10.1016/j.clpt.2004.12.118
Nanocrystalline silver inhibits antibiotic-, antiseptic-resistant bacteria
J. B. Lyczak PhD and P. J. Schechter MD, PhD
Clin Pharmacol Ther 77: P60-P60; doi:10.1016/j.clpt.2004.12.119
Imaging the distribution and clearance of a rectal microbicide gel and semen surrogate in the lower gastrointestinal tract
E. Fuchs PA-C, MBA, R. Wahl MD, K. Macura MD, J. Leal PhD, L. Grohskopf MD and C. Hendrix MD
Clin Pharmacol Ther 77: P60-P60; doi:10.1016/j.clpt.2004.12.120
Phenotypic evaluation of CYP2C9 by way of phenytoin metabolic ratio (PMR)
L. Adar MSc, M. Bialer PhD, MBA, M. Muszkat MD and Y. Caraco MD
Clin Pharmacol Ther 77: P60-P60; doi:10.1016/j.clpt.2004.12.121
Phenytoin metabolic ratio (PMR) correlates with formation clearance of (S)-7-OH-warfarin
L. Adar MSc, M. Bialer PhD, MBA, S. Blotnick PhD and Y. Caraco MD
Clin Pharmacol Ther 77: P61-P61; doi:10.1016/j.clpt.2004.12.122
Heritability of metformin renal clearance
M. Leabman PhD, C. Brown PharmD, J. Chung, R. Castro MD, G. E. Swan PhD, E. Lin PhD and K. M. Giacomini PhD
Clin Pharmacol Ther 77: P61-P61; doi:10.1016/j.clpt.2004.12.123
Determination of response to taxol/carboplatin in ovarian cancer patients
T. N. Frudakis PhD, M. Thomas PhD, Z. Gaskin BS and H. J. Gomez MD, PhD
Clin Pharmacol Ther 77: P61-P61; doi:10.1016/j.clpt.2004.12.124
Role of HNF-1 in the regulation of UGT1A1, UGT1A9 and UGT2B7 MRNA expression
S. Mirkov MS, F. Innocenti MD, PhD, W. Liu PhD, P. X. Chen MD, J. Ramirez MS, S.D. Undevia MD, S. Das PhD and M. J. Ratain MD
Clin Pharmacol Ther 77: P61-P61; doi:10.1016/j.clpt.2004.12.125
Verapamil-induced PR prolongation is influenced by CYP3A5 genotype
Y. Jin MD, Y. Wang PhD, H. Ho MD, J. Hilligoss, D. A. Flockhart MD, PhD and S. D. Hall PhD
Clin Pharmacol Ther 77: P62-P62; doi:10.1016/j.clpt.2004.12.126
Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam in Brazilians
J. Perini PharmD, R. Vianna-Jorge PhD and G. Suarez-Kurtz MD
Clin Pharmacol Ther 77: P62-P62; doi:10.1016/j.clpt.2004.12.127
Time dependent expression of MDR-1 in stable male renal transplant recipients
K. Tornatore PharmD, D. Brazeau PhD, K. Dole PharmD, K. Gillis PharmD, N. Leca MD, S. Yassa MD and R. Venuto MD
Clin Pharmacol Ther 77: P62-P62; doi:10.1016/j.clpt.2004.12.128
Evolution of the pregnane X receptor: Role of cross-species differences in biliary bile salts
M. D. Krasowski MD, PhD, K. Yasuda BS, L. R. Hagey PhD, E. G. Schuetz PhD and A. Di Rienzo PhD
Clin Pharmacol Ther 77: P62-P62; doi:10.1016/j.clpt.2004.12.129
Angiotensin system polymorphisms and traditional risk factors as predictors of heart failure prognosis
A. A. Hudson, I. Zineh PharmD, H. N. Yarandi PhD, T. Y. Langaee PhD, D. F. Pauly MD, PhD and J. A. Johnson PharmD
Clin Pharmacol Ther 77: P63-P63; doi:10.1016/j.clpt.2004.12.130
Identification of germline genetic variations in the 5' region of the estrogen receptor beta gene
S. Philips BS, A. Bermes BS, A. T. Nguyen BS, R. Luzcando BS, P. B. Narayanan PhD, D. A. Flockhart MD, PhD and T. C. Skaar PhD
Clin Pharmacol Ther 77: P63-P63; doi:10.1016/j.clpt.2004.12.131
Identification of genetic polymorphisms in 40 chemotherapy pathway genes
R.R. Freimuth PhD, S. Marsh PhD, M. Xiao PhD, P. Kwok MD, PhD and H. L. McLeod PharmD
Clin Pharmacol Ther 77: P63-P63; doi:10.1016/j.clpt.2004.12.132
Tamoxifen therapy reduced platelet counts without change in platelet function
Y. Jin MD, B. Ward, A. Storniolo MD, Z. Desta PhD, A. Nguyen, D. Hayes MD, V. Stearns MD and D. A. Flockhart MD, PhD
Clin Pharmacol Ther 77: P63-P63; doi:10.1016/j.clpt.2004.12.133
Is pharmacokinetics of stiripentol linear?
E. Rey PharmD, V. Jullien PharmD, P. D'Athis PhD, J. Vincent PharmD and G. Pons MD, PhD
Clin Pharmacol Ther 77: P64-P64; doi:10.1016/j.clpt.2004.12.134
Pharmacogenetic profiling of drug metabolizing enzyme genes
P. H. Hendolin PhD, J. Blievernicht, E. Schaeffeler, U. Ristonmaa, A. Liikola, P. Kolu, K. Klein, J. Aalto, U. Zanger and V. Korhonen
Clin Pharmacol Ther 77: P64-P64; doi:10.1016/j.clpt.2004.12.135
Multiple OATP transporters mediate the cellular uptake of rosuvastatin
R. H. Ho MD, Y. Wang PhD, B. F. Leake BS and R. B. Kim MD
Clin Pharmacol Ther 77: P64-P64; doi:10.1016/j.clpt.2004.12.136
Haplotype structures of cyclooxygenase genes in human ethnic populations
H. Kim DDS, PhD and R. A. Dionne DDS, PhD
Clin Pharmacol Ther 77: P64-P64; doi:10.1016/j.clpt.2004.12.137
Mixed or dynamic trial design: New methodology of research for pharmacogenetics and pharmacogenomics studies
P. Farahani MD and M. Levine MD, MSc
Clin Pharmacol Ther 77: P65-P65; doi:10.1016/j.clpt.2004.12.138
In vivo selection of inflammation markers on leukocytes in ischemic hearts
M. O. Schmidt PhD, T. Schober, A. Wellstein MD, PhD and B. C. Knollmann MD, PhD
Clin Pharmacol Ther 77: P65-P65; doi:10.1016/j.clpt.2004.12.139
Menstrual function during methadone maintenance (MM)
K. L. Preston PhD, J. Schmittner MD, J. R. Schroeder PhD and D. H. Epstein PhD
Clin Pharmacol Ther 77: P65-P65; doi:10.1016/j.clpt.2004.12.140
Combined administration of duloxetine (DU) and lorazepam (LO): A pharmacokinetic (PK) and pharmacodynamic (PD) study
S. Chalon PhD, MD, F. Vandenhende PhD and S. Ertle PhD
Clin Pharmacol Ther 77: P65-P65; doi:10.1016/j.clpt.2004.12.141
Pharmacokinetic(PK)/pharmacodynamic(PD) evaluation of CHF 2819.01 (novel cholinesterase inhibitor) in patients with probable Alzheimer's disease
S. S. Jhee PharmD, L. Fabbri PhD, V. Zarotsky PharmD, A. Piccinno, M. Rosenthal DO, S. V. Moran and L. Ereshefsky PharmD
Clin Pharmacol Ther 77: P66-P66; doi:10.1016/j.clpt.2004.12.142
Orthostatic intolerance induced by the 5-HT2C antagonist SB-247853 in healthy volunteers during head-up tilting
J. G. Theis MD, C. M. McEniery PhD, K. Maltby BSc, P. Overend BSc(Hons), J. A. Price MSc(Hons), T. Smith MD, T. Ostenfeld MD, PhD, I. Wilkinson BA MA DM MRCP and J. Brown MA MD FRCP FRES FMedSci
Clin Pharmacol Ther 77: P66-P66; doi:10.1016/j.clpt.2004.12.143
A randomized double-blind placebo-controlled 4-way crossover study investigating the residual psychomotor and cognitive effects of single oral doses of a new zolpidem modified-release formulation in healthy elderly volunteers
I. Hindmarch PhD, E. Legangeux and I. Zobouyan
Clin Pharmacol Ther 77: P66-P66; doi:10.1016/j.clpt.2004.12.144
Comparison of continuous and ordered categorical psychometric scales in measuring the time course of lorazepam induced somnolence
M. A. Kamal PharmD, A. Moton PharmD, R. Morlock PhD, D. Feltner MD and D. Ouellet PhD
Clin Pharmacol Ther 77: P66-P66; doi:10.1016/j.clpt.2004.12.145
A randomised, double blind, placebo controlled single ascending dose study of PYM50018, with an open label cross-over stage to assess food effect
D. H. Wessels MBChB, MBA, R. Grover FRCA, A. Frend PhD, S. Levene FRCPCH and L. Potgieter PhD
Clin Pharmacol Ther 77: P67-P67; doi:10.1016/j.clpt.2004.12.146
Acute effects of cigarette smoking on global cerebral blood flow (GCBF) in overnight abstinent tobacco smokers
T. Shinohara, K. Nagata, E. Yokoyama MD, M. Sato MD, S. Matsuoka, I. Kanno, J. Hatazawa and E. F. Domino MD
Clin Pharmacol Ther 77: P67-P67; doi:10.1016/j.clpt.2004.12.147
Disposition of nicotine and cotinine in rat blood and brain tissue, and their effects on striatal concentrations of dopamine and serotonin
Y. L. Chang PhD, P. L. Tsai PhD, L. C. Hung BS, Y. C. Chou PhD, J. H. Tien MS and T. H. Tsai PhD
Clin Pharmacol Ther 77: P67-P67; doi:10.1016/j.clpt.2004.12.148
Patient satisfaction with transdermal oxybutynin: Interim results from the matrix study
R. Goldberg MD, MPH, P. Sand MD, N. Dahl and T. Lackner PharmD
Clin Pharmacol Ther 77: P67-P67; doi:10.1016/j.clpt.2004.12.149
Safety, tolerability, and pharmacokinetics of idebenone in a dose-escalation trial in patients with Friedreich's ataxia
N.A. Di Prospero MD, PhD, C. Sumner MD, A. Atkinson MD, K. Fischbeck MD and J. P. Taylor MD, PhD
Clin Pharmacol Ther 77: P68-P68; doi:10.1016/j.clpt.2004.12.150
Neurotoxic pyridinium metabolites of haloperidol, HPP+ and RHPP+, are transported by a subset of membrane transporters
H. Kang MS, J. Ryu MD, S. Lee PhD, K. Liu PhD, J. Shim MD, PhD and J. Shin MD, PhD
Clin Pharmacol Ther 77: P68-P68; doi:10.1016/j.clpt.2004.12.151
Oral pharmacokinetics of doxapram in preterm infants
S. N. de Wildt MD, PhD, S. D. Sie MD, R. C. Dullemond MD, A. P. Vulto PharmD, PhD and J. N. van den Anker MD, PhD
Clin Pharmacol Ther 77: P68-P68; doi:10.1016/j.clpt.2004.12.153
Parental consent in pediatric clinical research
H. Chappuy MD, F. Doz MD, S. Blanche MD, PhD, J. Gentet, G. Pons MD, PhD and J. Treluyer MD, PhD
Clin Pharmacol Ther 77: P69-P69; doi:10.1016/j.clpt.2004.12.154
Use of hair cortisol as a biomarker for chronic stress in pregnancy
S. Kalra BSc Hon, J. Klein MSc, T. Karaskov MSc, C. Woodland PhD, A. Einarson RN and G. Koren MD
Clin Pharmacol Ther 77: P69-P69; doi:10.1016/j.clpt.2004.12.155
Stiripentol and severe myoclonic epilepsy in infancy (SMEI): A systematic review and a meta-analysis (metastiri) of individual patient data. Preliminary results
B. Kassai, C. Chiron, J. Treluyer, O. Dulac, J. Vincent, M. Cucherat, F. Gueyffier and G. Pons
Clin Pharmacol Ther 77: P69-P69; doi:10.1016/j.clpt.2004.12.156
Oxidative activation of linezolid to a reactive species: Implications for linezolid adverse drug reactions
S. Rieder, M. J. Tucker PhD and M. J. Rieder MD, PhD
Clin Pharmacol Ther 77: P69-P69; doi:10.1016/j.clpt.2004.12.157
Palatability of antiretroviral drugs in children with HIV: A survey of physician perceptions
M. J. Rieder MD, PhD, D. Lin BA, D. Matsui MD and S. King MD
Clin Pharmacol Ther 77: P70-P70; doi:10.1016/j.clpt.2004.12.158
Evaluation of the direct myocardial efects of dexmedetomidine in the transplanted infant heart
J. C. Finkel MD, Y. Johnson MD and J. van den Anker MD, PhD
Clin Pharmacol Ther 77: P70-P70; doi:10.1016/j.clpt.2004.12.159
The rationale for the use of an internet-based clinical trial to obtain safety, pharmacokinetic and pharmacodynamic data in a dose-escalation study in neonates, with hyperbilirubinemia, who need exchange transfusion
J. Mitchel PhD and B. Levinson MD
Clin Pharmacol Ther 77: P70-P70; doi:10.1016/j.clpt.2004.12.160
Hypoglycemia events associated with gatifloxacin and levofloxacin
S. Habis MD, J. F. Graumlich MD, R. R. Avelino PharmD, S. M. Salverson PharmD, K. Jamma MD, M. Gaddamanugu MD and J. C. Aldag PhD
Clin Pharmacol Ther 77: P70-P70; doi:10.1016/j.clpt.2004.12.161
Amiodarone induced pulmonary toxicity: An epidemiologic study
Y. Yamada MD, T. Shiga MD, M. Naganuma, N. Hagiwara MD and H. Kasanuki MD
Clin Pharmacol Ther 77: P71-P71; doi:10.1016/j.clpt.2004.12.162
Quality of antibiotic utilization for pneumonia in mental healthcare setting: Assessment through a computerized surveillance program in a university-affiliated psychiatric hospital
J. F. Westphal MD, PhD, C. Nonnenmacher PharmD and F. Jehl PharmD, PhD
Clin Pharmacol Ther 77: P71-P71; doi:10.1016/j.clpt.2004.12.163
Adverse events in a behavioral treatment trial in methadone maintenance
J. Schmittner MD, J. R. Schroeder PhD, D. H. Epstein PhD and K. L. Preston PhD
Clin Pharmacol Ther 77: P71-P71; doi:10.1016/j.clpt.2004.12.164
Impact of formulary policy on thiazolidinedione (TZD) use in the ontario drug benefit (ODB) program
M. Levine MD, MSc and K. Gaebel MSc
Clin Pharmacol Ther 77: P72-P72; doi:10.1016/j.clpt.2004.12.165
Increased prediction accuracy of adverse drug events using bayesian analysis
C. Hope PharmD and W. Rudman PhD
Clin Pharmacol Ther 77: P72-P72; doi:10.1016/j.clpt.2004.12.166
Multidisciplinary data review and analysis to fulfill NIH data sharing requirements via S-Plus server
C. E. Nicholson III, MS, M. Narayan MS, D. Patel MS, S. Vijayakumar PhD and J. S. Barrett PhD
Clin Pharmacol Ther 77: P72-P72; doi:10.1016/j.clpt.2004.12.167
Aprepitant has little inductive effect on CYP3A4 activity when coadministered with dexamethasone
S. A. Stoch, M. Fedgchin, A. Majumdar, C. Gargano, E. Pequignot, K. Gottesdiener, K. J. Petty, D. Panebianco and H. Greenberg
Clin Pharmacol Ther 77: P73-P73; doi:10.1016/j.clpt.2004.12.169
Effect of age and gender on the pharmacokinetics of solifenacin
R. Smulders MD, M. Taekema DVM PhD, W. Krauwinkel MSc and M. Raghoebar PhD
Clin Pharmacol Ther 77: P73-P73; doi:10.1016/j.clpt.2004.12.170
UGT1A1 and UGT1A9 variants affect thyroxine glucuronidation in human livers
A. Yoder Graber BA, F. Innocenti MD, PhD, J. Ramirez MS, P. X. Chen MD, S. Das PhD and M. J. Ratain MD
Clin Pharmacol Ther 77: P73-P73; doi:10.1016/j.clpt.2004.12.171
Influences of CYP2C9 genotype and fluvastatin on pharmacokinetics and pharmacodynamics of nateglinide
S. Uchida PhD, S. Nishio MD, X. D. Li MD, T. Ito MD, PhD, H. Morita MD, PhD, H. Nakamura MD, PhD, H. Yamada MD, PhD, H. Watanabe MD, PhD and K. Ohashi MD, PhD
Clin Pharmacol Ther 77: P74-P74; doi:10.1016/j.clpt.2004.12.172
In vitro studies and computer simulation of interactions between R483, a novel thiazolidinedione, and cytochrome P450 substrates
C. Weber PhD, C. Funk PhD, K. Frank PhD, A. MacDonald PhD and J. Charoin PharmD
Clin Pharmacol Ther 77: P74-P74; doi:10.1016/j.clpt.2004.12.173
Lack of effect of ketoconazole on the pharmacokinetics of oral bexarotene in healthy subjects
H. Kuan PhD, G. Loewen PhD and R. Geiser RN
Clin Pharmacol Ther 77: P74-P74; doi:10.1016/j.clpt.2004.12.174
Alvimopan (enteregTM), a novel opioid antagonist, achieves active systemic concentrations
J. Foss MD, V. Schmith PhD, B. Wallin MD, W. Du PhD and A. Melikian PhD
Clin Pharmacol Ther 77: P74-P74; doi:10.1016/j.clpt.2004.12.175
Inhibition of SN-38 glucuronidation by ketoconazole
W. Yong MBChB, J. Ramirez MS, F. Innocenti MD, PhD and M. J. Ratain MD
Clin Pharmacol Ther 77: P75-P75; doi:10.1016/j.clpt.2004.12.176
CYP2J2 metabolizes domperidone in guinea pig hearts
V. Michaud MSc, R. Masseé PhD and J. Turgeon PhD
Clin Pharmacol Ther 77: P75-P75; doi:10.1016/j.clpt.2004.12.177
Grapefruit juice inhibits CYP2A6 and nicotine metabolism
J. Hukkanen MD, PhD and N. L. Benowitz MD
Clin Pharmacol Ther 77: P75-P75; doi:10.1016/j.clpt.2004.12.178
Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine
A. Bergman PhD, A. Johnson-Levonas PhD, J. Burke MS, P. Larson MS, L. Zaru PhD, L. Reyderman PhD, P. Statkevich PhD, T. Kosoglou PharmD, G. Murphy MD, K. Gottesdiener MD and J. Paolini MD, PhD
Clin Pharmacol Ther 77: P75-P75; doi:10.1016/j.clpt.2004.12.179
Biochemical measures of hepatic function and bevacizumab clearance in patients with colorectal cancer: A population pharmacokinetic (PPK) approach
P. Kuebler PharmD, J. Lu PhD, L. Xu PhD, E. Holmgren PhD, J. Hambleton MD and D. Spyker MD
Clin Pharmacol Ther 77: P76-P76; doi:10.1016/j.clpt.2004.12.180
Pharmacokinetics, safety and tolerability of a novel 100 
g/h transdermal fentanyl patch co-administered with 100 mg oral naltrexone in healthy males
M. Lor BSc, GrDip, M. Di Marco PhD, J. Marier PhD, L. Roux MSc, N. Will BSc, E. Aggerholm Saedder MD and G. Morelli MD
Clin Pharmacol Ther 77: P76-P76; doi:10.1016/j.clpt.2004.12.181
Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects
B. Agoram PhD, L. Sutjandra BS and J. Sullivan MD
Clin Pharmacol Ther 77: P76-P76; doi:10.1016/j.clpt.2004.12.182
No interaction between nebivolol and digoxin in healthy volunteers
T. E. Lawrence PhD, S. Liu MS, J. W. Fisher BA, T. Vukic-Bugarski MD, C. M. Donnelly MS, M. Y. Huang PhD and R. J. Rackley PhD
Clin Pharmacol Ther 77: P76-P76; doi:10.1016/j.clpt.2004.12.183
Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers
A. A. Shaw PhD, J. Ziemniak PhD, S. Liu MS, S. W. Chervenick PhD and R. J. Rackley PhD
Clin Pharmacol Ther 77: P77-P77; doi:10.1016/j.clpt.2004.12.184
Herbal componets inhibit P-GP mediated digoxin transport in transwell cultured Caco-2 cell model
N. He PhD, X. Collins, Y. Huang and T. Edeki MD, PhD
Clin Pharmacol Ther 77: P77-P77; doi:10.1016/j.clpt.2004.12.185
Pharmacokinetics of nebivolol and ramipril are not affected by co-administration
T. L. Morton PhD, S. Liu MS, J. L. Phillips RN, C. M. Donnelly MS and R. J. Rackley PhD
Clin Pharmacol Ther 77: P77-P77; doi:10.1016/j.clpt.2004.12.186
Population pharmacokinetic (PPK) analysis of pegylated interferon alfa-2B (PEG-Intron) in patients with chronic myelogenous leukemia (CML)
S. Gupta PhD, D. Cutler MD, J. Jen PhD, K. Kolz and R. White PhD
Clin Pharmacol Ther 77: P77-P77; doi:10.1016/j.clpt.2004.12.187
Lack of effect of CYP3A4 inhibitor ketoconazole on transdermally administered buprenorphine
R. Noveck MD, S. Harris MD, A. El-Tahtawy PhD, R. Kim MD, B. Reidenberg MD, J. Chung PharmD and D. Chen PhD
Clin Pharmacol Ther 77: P78-P78; doi:10.1016/j.clpt.2004.12.188
Pharmacokinetics of a new amlodipine formulation: Bioequivalent and not affected by CYP3A5 genotype
J. Kim MD, J. Cho PhD, H. Jung, K. Lim MD, J. Chung MD, K. Yu MD, PhD, I. Jang MD, PhD and S. Shin MD, PhD
Clin Pharmacol Ther 77: P78-P78; doi:10.1016/j.clpt.2004.12.189
Gatifloxacin pharmacokinetics in healthy men and women
X. Zhang, B. R. Overholser, M. B. Kays and K. M. Sowinski
Clin Pharmacol Ther 77: P78-P78; doi:10.1016/j.clpt.2004.12.190
Two days of fluvoxamine dosing significantly inhibits CYP1A2
K. Bergman PharmD, S. E. Shoaf PhD and S. Mallikaarjun PhD
Clin Pharmacol Ther 77: P78-P78; doi:10.1016/j.clpt.2004.12.191
No pharmacokinetic interaction between nebivolol and furosemide in healthy subjects
T. L. Morton PhD, S. Liu MS, J. L. Phillips RN, C. M. Donnelly MS and R. J. Rackley PhD
Clin Pharmacol Ther 77: P79-P79; doi:10.1016/j.clpt.2004.12.192
In vitro letrozole N-dealkylation is mainly catalyzed by human cytochrome P450 (CYP) 3A
Z. Desta PhD, B. A. Ward BSc and D. A. Flockhart MD, PhD
Clin Pharmacol Ther 77: P79-P79; doi:10.1016/j.clpt.2004.12.193
Assessment of ethnic differences in the pharmacokinetics of valsartan
G. Sunkara PhD, C. Thang-Dittman PharmD, C. Yeh PhD, M. Ligueros-Saylan MD, P. Prasad PhD, N. Masuda, N. Koseki and Y. Fukui
Clin Pharmacol Ther 77: P79-P79; doi:10.1016/j.clpt.2004.12.194
Compartmental analysis of saquinavir (SQV) pharmacokinetics (PK)
J. Z. Zack, A. Forrest, O. O. Okusanya, S. Rosenkranz, M. F. Para, E. Adams, K. Yaresheski, R. C. Reichman and G. D. Morse
Clin Pharmacol Ther 77: P79-P79; doi:10.1016/j.clpt.2004.12.195
Pomelo juice but not cranberry juice affects the disposition of cyclosporine in humans
C. Fradette PhD, J. Grenier MSc, G. Morelli MD, J. Merritt PharmD, M. Vranderick DEC and M. P. Ducharme PharmD
Clin Pharmacol Ther 77: P80-P80; doi:10.1016/j.clpt.2004.12.196
Application of nonlinear mixed effects modeling in allometric interspecies scaling of emtricitabine
E. Abu-Raddad PhD and F.D. Boudinot PhD
Clin Pharmacol Ther 77: P80-P80; doi:10.1016/j.clpt.2004.12.197
Renal ontogeny of ifosfamide nephrotoxicity
K. Aleksa PhD, N. Halachmi PhD, S. Ito MD and G. Koren MD
Clin Pharmacol Ther 77: P80-P80; doi:10.1016/j.clpt.2004.12.198
Effect of co-administration of efavirenz and nelfinavir on the pharmacokinetics of indinavir
L. Labbeé PhD, G. Morse PharmD, M. A. Fischl MD, J. Feinberg MD, A. Collier, R. DiCenzo and L. B. Sheiner
Clin Pharmacol Ther 77: P80-P80; doi:10.1016/j.clpt.2004.12.199
Pharmacokinetics of (+)-methamphetamine (METH) and its metabolite (+)-amphetamine (AMP) in a METH self-administration paradigm in rats
A. Milesi-Halleé MD, D. E. McMillan PhD and S. M. Owens PhD
Clin Pharmacol Ther 77: P81-P81; doi:10.1016/j.clpt.2004.12.200
Muraglitazar does not alter the pharmacokinetics and pharmacodynamics of concomitantly administered warfarin in healthy subjects
A. Swaminathan PhD, C. Frost, S. Nepal, R. Raymond, D. Reitberg, R. Reeves and R. Mosqueda-Garcia
Clin Pharmacol Ther 77: P81-P81; doi:10.1016/j.clpt.2004.12.201
Effects of oral ketoconazole on renal function in healthy volunteers
P. C. Fernandez MD, D. W. Wallace MD, K. Ryan BSN, Q. Lin MBA and A. S. Hollister MD, PhD
Clin Pharmacol Ther 77: P81-P81; doi:10.1016/j.clpt.2004.12.202
Pharmacokinetics of cefdinir in healthy subjects after high protein diet and l-phenylalanine load
T. Fujita MD, PhD, A. Yamazaki MS, M. Ozaki MD, M. Majima MD, PhD, Y. Ohtani MD, PhD and Y. Kumagai MD, PhD
Clin Pharmacol Ther 77: P81-P81; doi:10.1016/j.clpt.2004.12.203
A CYP3A4 inhibitor increased the effect of cabergoline in the treatment of Parkinson's disease
A. Nakatsuka, M. Nagai, H. Yabe, T. Moritoyo and M. Nomoto
Clin Pharmacol Ther 77: P82-P82; doi:10.1016/j.clpt.2004.12.204
Absorption, metabolism, and excretion of (3H)-ospemifene following a single oral dose to post-menopausal women
S. Bryson PhD, K. Cornelissen PhD and M. Anttila MSc
Clin Pharmacol Ther 77: P82-P82; doi:10.1016/j.clpt.2004.12.205
No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 status
T. E. Lawrence PhD, C. Chien PhD, H. C. Tu MS, J. M. Phillips RN, C. M. Donnelly MS and M. Y. Huang PhD
Clin Pharmacol Ther 77: P82-P82; doi:10.1016/j.clpt.2004.12.206
An open-label, randomized, single-dose, dose-proportionality study of oral doses of a sustained-release formulation of desvenlafaxine succinate in healthy subjects
J. A. Behrle MS, A. I. Nichols PhD, S. B. McGrory RN, BSN and D. Raible MD
Clin Pharmacol Ther 77: P82-P82; doi:10.1016/j.clpt.2004.12.207
Impact of pharmacogenetics on drug interactions
C. Collins MD, I. Ragueneau MD, H. Hachad PharmD and R. Levy PhD
Clin Pharmacol Ther 77: P83-P83; doi:10.1016/j.clpt.2004.12.208
Pharmacokinetics (PK) and pharmacodynamics (PD) of daily lasofoxifene (LASO) in Japanese (J) and Caucasian (C) postmenopausal (PM) women
R. Fountaine PharmD, Y. Nishizawa PhD and M. J. Gardner PhD
Clin Pharmacol Ther 77: P83-P83; doi:10.1016/j.clpt.2004.12.209
Osmotic pseudoephedrine tablet: In vitro/in vivo correlation study
M. Befumo BS, E. Feleder MD, PhD, M. Coppari BS, M. Ricci PharmD and J. Faour PhD
Clin Pharmacol Ther 77: P83-P83; doi:10.1016/j.clpt.2004.12.210
The pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran when administered with azithromycin and cefuroxime
H. Dorani, K. Schützer, T. Sarich, U. Wall, L. Ohlsson and U. Eriksson
Clin Pharmacol Ther 77: P83-P83; doi:10.1016/j.clpt.2004.12.211
Bioavailability of adalimumab following subcutaneous injections in rheumatoid arthritis patients
R. Velagapudi PhD, P. Noertershauser PhD, W. Awni PhD, R. Granneman PhD and H. Kupper MD
Clin Pharmacol Ther 77: P84-P84; doi:10.1016/j.clpt.2004.12.212
Effect of grapefruit juice on cabergoline pharmacokinetics in patients with Parkinson's disease
M. Nagai MD, PhD, A. Nakatsuka, H. Yabe MD, T. Moritoyo MD, PhD and M. Nomoto MD, PhD
Clin Pharmacol Ther 77: P84-P84; doi:10.1016/j.clpt.2004.12.213
Clinical and in-vitro investigations to assess transporter based drug interaction potential of a partial alpha agonist R450
S. E. Bellibas MD, D. Schwab PhD, B. Liu MD, E. Gaudeul-Ehrhart MD, P. Weigl BS and A. Dorr
Clin Pharmacol Ther 77: P84-P84; doi:10.1016/j.clpt.2004.12.214
An ascending multiple-dose study of the safety and pharmacokinetics of a sustained-release formulation of desvenlafaxine succinate in healthy subjects
L. S. Richards MA, J. A. Behrle MS, A. I. Nichols PhD, R. J. Fruncillo MD, PhD and J. Paul PhD
Clin Pharmacol Ther 77: P84-P84; doi:10.1016/j.clpt.2004.12.215
A crossover study with single & divided-dose oral naloxone (NX), oral pentazocine/NX, & intravenous NX in healthy subjects
A. Singh MBBS, G. Apseloff MD, R. Colucci PharmD, S. C. Harris MD and V. Vashi PhD
Clin Pharmacol Ther 77: P85-P85; doi:10.1016/j.clpt.2004.12.216
The effect of epimedium koreanum on cytochrome P450 activity in human volunteers
J. Ryu MD, Y. Sunwoo MD, M. Go Bsc, P. M. Nauyen BSc, K. Liu PhD and J. Shin MD, PhD
Clin Pharmacol Ther 77: P85-P85; doi:10.1016/j.clpt.2004.12.217
The effect of Korean hot pepper on CYP2A6 activities in healthy subjects
Y. Sunwoo MD, J. Ryu MD, J. Shon MD, J. Kwak MS, D. Lee MS, P. M. Nguyen BSc, S. Lee PhD, K. Liu PhD and J. Shin MD, PhD
Clin Pharmacol Ther 77: P85-P85; doi:10.1016/j.clpt.2004.12.218
Pharmacokinetics (PK) of lasofoxifene (LASO), a next generation selective estrogen receptor modulator
M. J. Gardner PhD, D. Ouellet PhD, C. Bramson MD, D. Roman MD and E. Randinitis PhD
Clin Pharmacol Ther 77: P85-P85; doi:10.1016/j.clpt.2004.12.219
Population pharmacokinetics of amikacin in Korean adult patients
K. Park PhD, MD, M. Park MD, Y. Song MD, H. Kim BS, E. Noh BS and K. Kim MD, PhD
Clin Pharmacol Ther 77: P86-P86; doi:10.1016/j.clpt.2004.12.220
Population pharmacokinetics of aminophylline in Korean preterm infants using TDM data
M. Park MD, K. Park MD, PhD, Y. Song MD, H. Kim MS, S. Lee BS, K. Kim MD, PhD and J. Kim MD, PhD
Clin Pharmacol Ther 77: P86-P86; doi:10.1016/j.clpt.2004.12.221
An open-label, randomized, crossover study of the relative bioavailability of desvenlafaxine after oral administration of extended-release venlafaxine and sustained-release desvenlafaxine succinate in healthy subjects
A. I. Nichols PhD, A. Patat MD, PhD, S. Baird-Bellaire PhD, J. A. Behrle MS and P. Chretien MD
Clin Pharmacol Ther 77: P86-P86; doi:10.1016/j.clpt.2004.12.222
Pharmacokinetics of DX-8951 in pediatric cancer patients
M. Trinh MSc, P. Colucci BSc, M. Kamida MS, M. Danna OCN, R. De Jager MD, T. Trippett MD and M. P. Ducharme PharmD, MDS Pharma Services
Clin Pharmacol Ther 77: P86-P86; doi:10.1016/j.clpt.2004.12.223
An exploratory analysis of exposure-toxicity (E-T) relationships with oblimersen sodium; potential for patient management
V. J. Sekar PhD, J. Barrett PhD, R. Chandula MS and G. Menard PharmD
Clin Pharmacol Ther 77: P87-P87; doi:10.1016/j.clpt.2004.12.224
Prediction of pharmacokinetics of antibiotics in patients receiving hemodialysis
N. Tajima, S. Nagashima, H. Torii, T. Uematsu, M. Tajima, H. Naganuma and A. Hishida
Clin Pharmacol Ther 77: P87-P87; doi:10.1016/j.clpt.2004.12.225
The effect of dietary salt on verapamil disposition in relation to MDR1 C3435T / G2677T genotype
J. Ryu MD, Y. Sunwoo MD, J. Shon MD, D. Lee MS, K. Liu PhD, I. Cha MD, PhD and J. Shin MD, PhD
Clin Pharmacol Ther 77: P87-P87; doi:10.1016/j.clpt.2004.12.226
A Bayesian analysis of published pharmacokinetic data - a ketoconazole example
L. Li PhD, M. Yu PhD, A. Lucksiri MD and S. Hall PhD
Clin Pharmacol Ther 77: P87-P87; doi:10.1016/j.clpt.2004.12.227
Pregabalin exposure-response analysis in patients with postherpetic neuralgia
S. Chapel PhD, K. Kowalski MS, M. Hutmacher MS and H. Bockbrader PhD
Clin Pharmacol Ther 77: P88-P88; doi:10.1016/j.clpt.2004.12.228
Population pharmacokinetics of carvedilol in pediatric patients with congestive heart failure
S. Laer MD, PhD, S. Albers, M. Gupta, T. S. Mir and B. Meibohm
Clin Pharmacol Ther 77: P88-P88; doi:10.1016/j.clpt.2004.12.229
Application of monte carlo simulations to identify an appropriate dosage strategy for patients receiving a continuous intravenous infusion of enoxaparin
Y. Feng MS, B. Green PhD, S. B. Duffull PhD, S. L. Kane PharmD, MSc, M. B. Bobek PharmD and R. R. Bies PharmD, PhD
Clin Pharmacol Ther 77: P88-P88; doi:10.1016/j.clpt.2004.12.230
A pharmacokinetics and pharmacodynamic model of nitroglycerin (NTG) effects on cerebral blood flow (CBF) and mean velocity (MV)
E. Shang PhD, A. Forrest PharmD, Q. Ma PhD, N. W. Fucile PharmD and E. M. Bednarczyk PharmD
Clin Pharmacol Ther 77: P89-P89; doi:10.1016/j.clpt.2004.12.231
Population PK analysis of DX-9065A in patients with acute coronary syndrome
M. Yamaguchi PhD, S. Kunitada PhD and R. Wada
Clin Pharmacol Ther 77: P89-P89; doi:10.1016/j.clpt.2004.12.232
Population pharmacokinetic-pharmacodynamic modeling of efaproxiral in cancer patients receiving radiation therapy
M. R. Gastonguay PhD, J. Venitz MD, PhD, R. Steffen PhD and J. Hackman
Clin Pharmacol Ther 77: P89-P89; doi:10.1016/j.clpt.2004.12.233
Pharmacokinetics and pharmacodynamics of azithromycin in gerbils with haemophilus influenzae middle ear infection
O. O. Okusanya PharmD, A. Forrest PharmD, B. M. Booker PharmD, S. M. Bhavnani PharmD, D. Girard MS, S. M. Finegan MS, MBA, J. C. Hamel MS, S. B. Seibel BS, L. J. Benincosa PhD, A. Sharma PhD, P. Liu PhD, L. D. Kendall MS, P. B. Inskeep PhD and P. G. Amrbrose PharmD
Clin Pharmacol Ther 77: P89-P89; doi:10.1016/j.clpt.2004.12.234
Cost-efficient higher-order crossover designs in comparative bioavailability studies
J. Zhou MD, PhD, Y. Yuan MS, R. Reynolds BS and S. Raber PharmD
Clin Pharmacol Ther 77: P90-P90; doi:10.1016/j.clpt.2004.12.235
Optimal sparse pharmacokinetic (PK) sampling strategies (OSS) for multi-drug antiretroviral (ARV) regimens
J. Z. Zack, A. Forrest, Q. Ma, S. Rosenkranz, M. F. Para, E. Adams, R. C. Reichman, K. Yaresheski and G. D. Morse
Clin Pharmacol Ther 77: P90-P90; doi:10.1016/j.clpt.2004.12.236
Population pharmacodynamic modeling of zolmitriptan following administration of conventional tablets
J. Li PhD, H. Kimko PhD, R. Bies PharmD, PhD, C. Peck MD, H. Su PhD and K. McKenna PhD
Clin Pharmacol Ther 77: P90-P90; doi:10.1016/j.clpt.2004.12.237
A non-linear mixed effect dynamic model using adherence to treatment to describe long-term therapy outcome in HIV-patients
L. Labbeé PhD and D. Verotta PhD
Clin Pharmacol Ther 77: P90-P90; doi:10.1016/j.clpt.2004.12.238
Population PK/PD analysis of DX-8951F when administered to cancer patients
C. Seng Yue BPharm, MSc, J. Lavigne MSc, P. Colucci BSc, M. Kamida MS, R. De Jager MD, M. Yamaguchi PhD and M. P. Ducharme PharmD
Clin Pharmacol Ther 77: P91-P91; doi:10.1016/j.clpt.2004.12.239
A population pharmacokinetic (PK) analysis of ABX-IL8, a fully human monoclononal IGG2 antibody, in psoriasis patients
B. Wang PhD, L. Roskos PhD, K. Osborn BS, H. Lu MS, M. Kim BS, R. Pasumarthi BS, N. Raie MS and M. Tabrizi PhD
Clin Pharmacol Ther 77: P91-P91; doi:10.1016/j.clpt.2004.12.240
Non-parametric pharmacokinetic method for assessment of the variance of lifespan distribution of blood cells
W. Krzyzanski PhD
Clin Pharmacol Ther 77: P91-P91; doi:10.1016/j.clpt.2004.12.241
Evaluation of the effect of residual error covariance for a parent-metabolite population pharmacokinetic model
B. E. Houk PhD, M. R. Gastonguay PhD and M. Amantea PharmD
Clin Pharmacol Ther 77: P91-P91; doi:10.1016/j.clpt.2004.12.242
Population pharmacokinetics of esomeprazole in adult patients with gastroesophageal reflux disease
J. Li PhD, T. Lind MD, PhD, T. Tzeng PhD, B. Birmingham PhD, J. Zhao MD, PhD, T. Andersson PhD, P. Martin MD and P. Lundborg MD, PhD
Clin Pharmacol Ther 77: P92-P92; doi:10.1016/j.clpt.2004.12.243
Neural network model of orbofiban pharmacodynamics from sparse phase-II data
D. E. Mager PharmD, PhD, J. D. Shirey MS, D. Cox PhD, D. J. Fitzgerald MD and D. R. Abernethy MD, PhD
Clin Pharmacol Ther 77: P92-P92; doi:10.1016/j.clpt.2004.12.244
A population pharmacokinetic/pharmacodynamic model for the mobilization of progenitor cells by AMD3100
B. Green MSc DPh, H. Lee MD, PhD, N. Lack BSc, D. Dale MD, G. Calandra MD, PhD, R. MacFarland PhD, K. Badel BSc, W. Liles MD, PhD, G. Bridger PhD and C. Peck MD
Clin Pharmacol Ther 77: P92-P92; doi:10.1016/j.clpt.2004.12.245
Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of etanercept in patients with juvenile rheumatoid arthritis (JRA) using a dichotomous clinical endpoint
D. Yim MD, PhD, H. Zhou PhD, C. C. Peck MD and H. Lee MD, PhD
Clin Pharmacol Ther 77: P92-P92; doi:10.1016/j.clpt.2004.12.246
Does sex affect theophylline Emax? A mixture model method
N. Holford MD and S. Duffull PhD
Clin Pharmacol Ther 77: P93-P93; doi:10.1016/j.clpt.2004.12.247
Population PK analysis of DX-8951F when administered to cancer patients
P. Colucci BSc, J. Lavigne MSc, M. Kamida MS, R. De Jager MD, M. Yamaguchi PhD and M. P. Ducharme PharmD
Clin Pharmacol Ther 77: P93-P93; doi:10.1016/j.clpt.2004.12.248
The Lasagna pain scale (LPS)
B. P. Schachtel MD, J. D. Kohles PhD, S. Pan PhD and K. M. Sanner RN
Clin Pharmacol Ther 77: P93-P93; doi:10.1016/j.clpt.2004.12.249
Ongoing regional prevalence study of fetal alcohol exposure as determined by Meconium analysis of fatty acid ethyl esters
J. Gareri HBSc and G. Koren MD
Clin Pharmacol Ther 77: P93-P93; doi:10.1016/j.clpt.2004.12.250
Effect of maximal therapeutic acetaminophen (APAP) dosing in alcoholics
E. K. Kuffner MD, J. L. Green PhD, G. M. Bogdan PhD, P. Knox PhD and R. C. Dart MD, PhD
Clin Pharmacol Ther 77: P94-P94; doi:10.1016/j.clpt.2004.12.251
Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high-dose chemotherapy
M. E. de Jonge PharmD, A. D. Huitema, A. C. Tukker, S. M. Van Dam, S. Rodenhuis and J. H. Beijnen
Clin Pharmacol Ther 77: P94-P94; doi:10.1016/j.clpt.2004.12.252
Plasma levels of bupropion (BUP), major metabolites and antidepressant response in juveniles
J. M. Perel PhD, W. B. Daviss MD, G. R. Rudolph BS, D. A. Axelson MD, S. Nuss RN and D. A. Brent MD
Clin Pharmacol Ther 77: P94-P94; doi:10.1016/j.clpt.2004.12.253
Effect of cobalt sulfate on histopathological features of liver in rat
F. Mozaffarian, A. Zakerifar, J. Alaii, H. Saadat and P. Passaebakhsh
Clin Pharmacol Ther 77: P94-P94; doi:10.1016/j.clpt.2004.12.254
Ecabet raises calcitonin-gene related peptide and substance P in human plasma
F. Katagiri, S. Inoue, Y. Sato, H. Itoh PhD and M. Takeyama PhD
Clin Pharmacol Ther 77: P95-P95; doi:10.1016/j.clpt.2004.12.255
Pralidoxime may be needed to be given continually more than 72h to serious patients with organophosphate poisoning
F. Fu MD, C. Su and Y. Liu
Clin Pharmacol Ther 77: P95-P95; doi:10.1016/j.clpt.2004.12.256
Human thiopurine S-methyltransferase (TPMT) pharmacogenetics: Variant allozyme aggresome formation
L. Wang MD, PhD and R. Weinshilboum MD
Clin Pharmacol Ther 77: P95-P95; doi:10.1016/j.clpt.2004.12.257
Ontogeny of various solute carrier family (SLC) transporter expression in human pediatric liver biopsies
L. Tang PharmD, M. Gupta BPharm, C. Zamber PhD, E. Schuetz PhD and B. Meibohm PhD
Clin Pharmacol Ther 77: P95-P95; doi:10.1016/j.clpt.2004.12.258
Human sulfotransferase (SULT) 1A1 pharmacogenetics: Intragene haplotype, breast cancer and mammographic breast density
A. Adjei PhD, J. Olson PhD, C. Vachon PhD, R. Vierkant MS, V. Pankratz PhD, K. Brandt MD, Z. Fredericksen BS, T. Sellers PhD, MPH and R. Weinshilboum MD
Clin Pharmacol Ther 77: P96-P96; doi:10.1016/j.clpt.2004.12.259
Functional heterogeneity of polymorphisms in the human organic anion transporter, OAT3 (SLC22A8)
A. R. Erdman MD, C. Brown PharmD, R. Castro MD, T. Taylor, E. Carlson and K. M. Giacomini PhD
Clin Pharmacol Ther 77: P96-P96; doi:10.1016/j.clpt.2004.12.260
The effect of genetic polymorphisms on warfarin pharmacodynamics
R. Loebstein MD, D. Kurnik MD, H. Halkin, M. Vecsler MD, E. Gak MD and S. Almog PhD
Clin Pharmacol Ther 77: P96-P96; doi:10.1016/j.clpt.2004.12.261
Individualized treatment strategy for H. pylori infection based on the susceptibility of H. pylori to antibiotics and CYP2C19 genotypes
T. Furuta MD, PhD, N. Shirai MD, PhD, M. Kodaira MD, PhD, M. Sugimoto MD, A. Nakamura MD, Y. Sagehashi MS, K. Kenmotsu MS, M. Nagano PhD, T. Egashira MS, K. Ueda PhD, M. Yoneyama PhD, A. Hishida MD, PhD, K. Ohashi MD, PhD and T. Ishizaki
Clin Pharmacol Ther 77: P96-P96; doi:10.1016/j.clpt.2004.12.262
Variable blood pressure response to verapamil by KCNMB1 genotype
A. L. Beitelshees PharmD, Y. Gong PhD, R. M. DeHoff PharmD, J. I. Moss PhD, C. J. Pepine MD and J. A. Johnson PharmD
Clin Pharmacol Ther 77: P97-P97; doi:10.1016/j.clpt.2004.12.263
Association of corticotropin releasing factor receptor-2 variants with response to inhaled glucocorticoids in asthma
E. S. Silverman MD, S. L. Lake PhD, K. G. Tantisira MD, B. G. Richter PhD, A. A. Litonjua MD, R. Lazarus MD, J. Valone BS, S. A. Shore PhD and S. T. Weiss MD
Clin Pharmacol Ther 77: P97-P97; doi:10.1016/j.clpt.2004.12.264
Novel approach to therapeutic drug monitoring of nevirapine in pediatric HIV infected patients
N. Y. Rakhmanina MD, S. J. Soldin PhD, H. M. Spiegel MD, PhD, J. Sever MD and J. N. van den Anker MD, PhD
Clin Pharmacol Ther 77: P97-P97; doi:10.1016/j.clpt.2005.01.001
Pharmacokinetics of ondansetron in very young pediatric patients
B. M. Johnson PhD, L. J. Haberer PhD, M. E. Sale MD and J. F. Hoke PhD
Clin Pharmacol Ther 77: P97-P97; doi:10.1016/j.clpt.2005.01.002
Positron emission tomography to quantify brain nicotine abstinence
E. F. Domino MD and H. Tsukada PhD
Clin Pharmacol Ther 77: P98-P98; doi:10.1016/j.clpt.2005.01.003
Reduction of haloperidol-induced side effects by ACP-103 in healthy volunteers
A. E. Grahnen PhD, K. E. Vanover PhD, D, M. Weiner PhD, L. Nilsson MD, B. Tolf PhD, U. Hacksell PhD and M. R. Davis PhD
Clin Pharmacol Ther 77: P98-P98; doi:10.1016/j.clpt.2005.01.004
An open-label clinical evaluation of tigecycline (TGC) concentrations in selected tissues and fluids
M. H. Gotfried MD, K. A. Rodvold PharmD, M. Cwik PhD, S. M. Troy MS, G. Dukart MD and E. J. Ellis-Grosse PhD
Clin Pharmacol Ther 77: P98-P98; doi:10.1016/j.clpt.2005.01.005
Major features of dose omissions in 87 ambulatory drug trials
B. Vrijens PhD, E. Tousset MSc, P. Gaillard, J. Meétry PhD and J. Urquhart MD
Clin Pharmacol Ther 77: P99-P99; doi:10.1016/j.clpt.2005.01.006
Neuroimaging studies in CNS drugs approved from 1995 to 2004
R. S. Uppoor MPharm, PhD, S. U. Yasuda MS, PharmD, P. Mummaneni PhD, E. Cooper, H. Pien PhD, MBA, G. Sorensen MD, J. Collins PhD and M. U. Mehta PhD, FDA
Clin Pharmacol Ther 77: P99-P99; doi:10.1016/j.clpt.2005.01.007
Therapeutic benefit of a KATP-channel opening drug in cocaine toxicity
S. Reyes BS, L. Zingman MD, G. C. Kane MD, S. Yamada MD, PhD, T. Miki MD, PhD, S. Seino MD, DMSci and A. Terzic MD, PhD
Clin Pharmacol Ther 77: P99-P99; doi:10.1016/j.clpt.2005.01.008
Author index
Index to abstract authors
Clin Pharmacol Ther 77: P100-P107; doi:10.1016/S0009-9236(05)00020-2
